Fibroblast growth factor/fibroblast growth factor recep

Cytokine and Growth Factor Reviews 16, 159-178

DOI: 10.1016/j.cytogfr.2005.01.004

Citation Report

#	Article	IF	CITATIONS
1	Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells. International Journal of Oncology, 1992, 34, 355.	1.4	10
2	Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncology Reports, 1994, 21, 211.	1.2	22
4	Fragile X and company: Finding the right diagnosis. Neurology, 2005, 65, E3-E4.	1.5	7
5	NIR Spectroscopic Detection of Breast Cancer. Technology in Cancer Research and Treatment, 2005, 4, 497-512.	0.8	80
6	FGF2 Binding, Signaling, Angiogenesis Are Modulated by Heparanase in Metastatic Melanoma Cells. Neoplasia, 2006, 8, 596-606.	2.3	76
7	Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?. Respiratory Research, 2006, 7, 82.	1.4	42
8	GLYCOMICS APPROACH TO STRUCTURE-FUNCTION RELATIONSHIPS OF GLYCOSAMINOGLYCANS. Annual Review of Biomedical Engineering, 2006, 8, 181-231.	5.7	257
9	Finding a Needle in a Haystack:Â Development of a Combinatorial Virtual Screening Approach for Identifying High Specificity Heparin/Heparan Sulfate Sequence(s). Journal of Medicinal Chemistry, 2006, 49, 3553-3562.	2.9	68
10	Structural Requirements of FGF-1 for Receptor Binding and Translocation into Cellsâ€. Biochemistry, 2006, 45, 15338-15348.	1.2	8
11	Mitogenic and chondrogenic effects of fibroblast growth factor-2 in adipose-derived mesenchymal cells. Biochemical and Biophysical Research Communications, 2006, 343, 644-652.	1.0	122
12	Stromal cell-derived factor 1 (CXCL12) binds to endothelial cells and signals through a receptor different from CXCR4. Biochemical and Biophysical Research Communications, 2006, 348, 192-199.	1.0	10
13	Thrombin induces rapid PAR1-mediated non-classical FGF1 release. Biochemical and Biophysical Research Communications, 2006, 350, 604-609.	1.0	20
14	Crkl Deficiency Disrupts Fgf8 Signaling in a Mouse Model of 22q11 Deletion Syndromes. Developmental Cell, 2006, 10, 71-80.	3.1	138
15	Vaccines targeting tumour angiogenesis—a novel strategy for cancer immunotherapy. European Journal of Surgical Oncology, 2006, 32, 363-370.	0.5	39
16	The role of syndecans in disease and wound healing. Matrix Biology, 2006, 25, 443-456.	1.5	139
17	Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells. Molecular and Cellular Endocrinology, 2006, 253, 36-43.	1.6	15
18	 Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling. Brazilian Journal of Medical and Biological Research, 2006, 39, 157-167.	0.7	63
19	Negative regulation of primitive hematopoiesis by the FGF signaling pathway. Blood, 2006, 108, 3335-3343.	0.6	66

#	Article	IF	Citations
20	Mesenchymal Stem Cells and the Treatment of Cardiac Disease. Experimental Biology and Medicine, 2006, 231, 39-49.	1.1	121
21	Ocular neuromyotonia secondary to a cavernous sinus meningioma. Neurology, 2006, 66, 1598-1599.	1.5	27
22	The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. Journal of Pathology, 2006, 208, 431-438.	2.1	35
23	EXTRACELLULAR MATRIX AS A BIOACTIVE MATERIAL FOR SOFT TISSUE RECONSTRUCTION. ANZ Journal of Surgery, 2006, 76, 1096-1100.	0.3	78
24	Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2006, 35, 136-139.	1.4	43
25	A functional genomics approach to the mode of action of apratoxin A. Nature Chemical Biology, 2006, 2, 158-167.	3.9	154
26	Role of angiogenesis in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 515-523.	0.9	95
27	Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer and Metastasis Reviews, 2006, 25, 333-356.	2.7	163
28	Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer and Metastasis Reviews, 2006, 25, 373-385.	2.7	80
29	Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clinical and Experimental Metastasis, 2006, 23, 75-86.	1.7	30
30	Soluble N-cadherin fragment promotes angiogenesis. Clinical and Experimental Metastasis, 2006, 23, 187-201.	1.7	37
31	Fibroblast Growth Factor-2 Augments Recombinant Human Bone Morphogenetic Protein-2-Induced Osteoinductive Activity. Annals of Biomedical Engineering, 2006, 34, 717-725.	1.3	32
32	Fibroblast growth factor-2 induces the activation of Src through Fes, which regulates focal adhesion disassembly. Experimental Cell Research, 2006, 312, 3015-3022.	1.2	19
33	Safrole oxide induced human umbilical vein vascular endothelial cell differentiation into neuron-like cells by depressing the reactive oxygen species level at the low concentration. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 247-253.	1.9	16
34	The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma. Seminars in Oncology, 2006, 33, 50-56.	0.8	172
35	Platelet-Derived Growth Factor–BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells. Trends in Cardiovascular Medicine, 2006, 16, 25-28.	2.3	109
36	Orthotopic expression of human 15-lipoxygenase (LO)-1 in the dorsolateral prostate of normal wild-type C57BL/6 mouse causes PIN-like lesions. Prostaglandins and Other Lipid Mediators, 2006, 81, 1-13.	1.0	7
37	Synthetic Oligosaccharide Stimulates and Stabilizes Angiogenesis: Structure-Function Relationships and Potential Mechanisms. Journal of Cardiovascular Pharmacology, 2006, 48, 6-13.	0.8	25

#	ARTICLE	IF	CITATIONS
38	Isolation and Characterization of Rat Pituitary Endothelial Cells. Neuroendocrinology, 2006, 83, 387-393.	1.2	12
39	Gastrointestinal Tumors: Metastasis and Tetraspanins. Zeitschrift Fur Gastroenterologie, 2006, 44, 573-586.	0.2	48
40	Transient downbeat nystagmus from West Nile virus encephalomyelitis. Neurology, 2006, 66, 1599-1600.	1.5	19
41	Reduced penetrance of intermediate size alleles in spinocerebellar ataxia type 10. Neurology, 2006, 66, 1602-1604.	1.5	38
42	The "Ets―Factor: Vessel Formation in Zebrafish—The Missing Link?. PLoS Biology, 2006, 4, e24.	2.6	7
43	Orthostatic tremor in monozygotic twins. Neurology, 2006, 66, 1600-1601.	1.5	26
44	Bilateral substantia nigra involvement in vaccine-associated poliomyelitis. Neurology, 2006, 66, 1597-1598.	1.5	7
45	A Critical Role for the Inflammatory Response in a Mouse Model of Preneoplastic Progression. Cancer Research, 2006, 66, 5676-5685.	0.4	67
46	Effect of Subconjunctivally Injected, Liposome-Bound, Low-Molecular-Weight Heparin on the Absorption Rate of Subconjunctival Hemorrhage in Rabbits., 2006, 47, 3968.		20
47	VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17260-17265.	3.3	142
49	Expression of a Fibroblast Growth Factor–Binding Protein during the Development of Adenocarcinoma of the Pancreas and Colon. Cancer Research, 2006, 66, 1191-1198.	0.4	42
50	Vesicular Trafficking of Tyrosine Kinase Receptors and Associated Proteins in the Regulation of Signaling and Vascular Function. Circulation Research, 2006, 98, 743-756.	2.0	113
51	Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt Signaling in Ovarian Endometrioid Adenocarcinomas. Cancer Research, 2006, 66, 1354-1362.	0.4	255
52	Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. Journal of Biological Chemistry, 2006, 281, 22605-22613.	1.6	101
53	New Vessel Formation in the Central Nervous System During Tumor Growth, Vascular Malformations, and Moyamoya. Current Neurovascular Research, 2006, 3, 237-245.	0.4	87
54	Co-occurrence of a cavernous malformation and contralateral moyamoya. Neurology, 2006, 66, 1601-1602.	1.5	10
55	IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase. Journal of Immunology, 2006, 177, 8266-8272.	0.4	71
56	Extracellular Angiogenic Growth Factor Interactions: An Angiogenesis Interactome Survey. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 93-111.	1.7	43

#	Article	IF	Citations
57	Concanavalin A, but Not Glycated Albumin, Increases Subendothelial Deposition of Von Willebrand Factor In Vitro. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 245-248.	1.7	7
58	Cytotoxicity of a Novel Fibroblast Growth Factor Receptor Targeted Immunotoxin on a Human Ovarian Teratocarcinoma Cell Line. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 321-332.	0.7	10
59	Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 515-522.	1.3	35
60	Identification of the Fibroblast Growth Factor (FGF)-interacting Domain in a Secreted FGF-binding Protein by Phage Display. Journal of Biological Chemistry, 2006, 281, 1137-1144.	1.6	31
61	Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy. Journal of Leukocyte Biology, 2006, 80, 572-580.	1.5	346
62	The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells. Molecular Pharmacology, 2007, 71, 695-703.	1.0	10
63	Peroxynitrite mediates VEGF's angiogenic signal and function via a nitrationâ€independent mechanism in endothelial cells. FASEB Journal, 2007, 21, 2528-2539.	0.2	74
64	Heparan sulphate synthetic and editing enzymes in ovarian cancer. British Journal of Cancer, 2007, 96, 1544-1548.	2.9	50
65	Targets for regulating angiogenesis in the ageing endothelium. Expert Opinion on Therapeutic Targets, 2007, 11, 1385-1399.	1.5	14
66	Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics, 2007, 8, 49-66.	0.6	52
67	Microvascular endowment in the developing chicken embryo lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1136-L1146.	1.3	53
68	Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1341-E1351.	1.8	14
69	Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies. Current Pharmaceutical Design, 2007, 13, 2025-2044.	0.9	134
70	Anatomic Site-Related Expression of Cancer-Associated Molecules in Ovarian Carcinoma. Current Cancer Drug Targets, 2007, 7, 109-120.	0.8	17
71	Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Human Reproduction, 2007, 22, 36-44.	0.4	40
72	Morphological Observation and In Vitro Angiogenesis Assay of Endothelial Cells Isolated From Human Cerebral Cavernous Malformations. Stroke, 2007, 38, 1313-1319.	1.0	30
73	Mechanistic Exploration of Phthalimide Neovascular Factor 1 Using Network Analysis Tools. Tissue Engineering, 2007, 13, 2561-2575.	4.9	11
74	CLINICAL AND FUNDAMENTAL ASPECTS OF ANGIOGENESIS AND ANTI-ANGIOGENESIS. Acta Clinica Belgica, 2007, 62, 162-169.	0.5	16

#	Article	IF	CITATIONS
75	Sca-1+ Hematopoietic Cell–based Gene Therapy with a Modified FGF-2 Increased Endosteal/Trabecular Bone Formation in Mice. Molecular Therapy, 2007, 15, 1881-1889.	3.7	18
76	Nonclassic Endogenous Novel Regulators of Angiogenesis. Pharmacological Reviews, 2007, 59, 185-205.	7.1	163
77	Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. Journal of Cell Biology, 2007, 177, 539-549.	2.3	107
78	Therapeutic Angiogenesis. Vascular and Endovascular Surgery, 2007, 41, 173-185.	0.3	14
79	Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R775-R783.	0.9	23
80	Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3937-3942.	3.3	57
81	Molecular Targets for Nutritional Preemption of Cancer. Current Cancer Drug Targets, 2007, 7, 410-415.	0.8	15
82	Identification of a Fibroblast Growth Factor Receptor 1 Splice Variant That Inhibits Pancreatic Cancer Cell Growth. Cancer Research, 2007, 67, 2712-2719.	0.4	28
83	Mammalian Tumor Xenografts Induce Neovascularization in Zebrafish Embryos. Cancer Research, 2007, 67, 2927-2931.	0.4	245
84	Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement. Journal of Biological Chemistry, 2007, 282, 19676-19684.	1.6	27
85	Methylmercury Retards the Repair of Wounded Monolayer of Human Brain Microvascular Endothelial Cells by Inhibiting Their Proliferation without Nonspecific Cell Damage. Journal of Health Science, 2007, 53, 450-456.	0.9	8
86	In Vivo Angiogenesis Is Suppressed by Unsaturated Vitamin E, Tocotrienol. Journal of Nutrition, 2007, 137, 1938-1943.	1.3	92
87	Molecular Targets for Promoting Wound Healing in Diabetes. Recent Patents on Endocrine, Metabolic $\&$ Immune Drug Discovery, 2007, 1 , 1 - 13 .	0.7	9
88	Ocular Neovascularization: Basic Mechanisms and Therapeutic Advances. Survey of Ophthalmology, 2007, 52, S3-S19.	1.7	118
89	The tyrosine phosphatase HD-PTP: A novel player in endothelial migration. Biochemical and Biophysical Research Communications, 2007, 364, 534-539.	1.0	42
90	Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells, Molecules, and Diseases, 2007, 39, 212-220.	0.6	299
91	Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Experimental Eye Research, 2007, 85, 323-327.	1.2	23
92	The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine and Growth Factor Reviews, 2007, 18, 327-334.	3.2	78

#	Article	IF	CITATIONS
93	1-O-Alkylglycerols reduce the stimulating effects of bFGF on endothelial cell proliferation in vitro. Cancer Letters, 2007, 251, 317-322.	3.2	13
94	The inflammatory response recapitulates phylogeny through trophic mechanisms to the injured tissue. Medical Hypotheses, 2007, 68, 202-209.	0.8	12
95	Notch2 Signaling Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth. American Journal of Pathology, 2007, 171, 1023-1036.	1.9	108
96	Cancer Biology. , 2007, , 1-31.		4
97	Structure-Based Virtual Screening of FGFR Inhibitors. BioDrugs, 2007, 21, 31-45.	2.2	10
98	Extracellular Matrix as a Strategy for Treating Chronic Wounds. American Journal of Clinical Dermatology, 2007, 8, 61-66.	3.3	53
99	Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches. Neurodegenerative Diseases, 2007, 4, 349-365.	0.8	64
100	Impact of vascular endothelial growth factor release on radiation resistance. Oncology Reports, 2007, , .	1.2	9
101	Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thrombosis and Haemostasis, 2007, 97, 355-363.	1.8	86
102	Photo-crosslinkable and biodegradable Pluronic/heparin hydrogels for local and sustained delivery of angiogenic growth factor. Journal of Biomedical Materials Research - Part A, 2007, 83A, 597-605.	2.1	70
103	Characterization of the surface immobilized synthetic heparin binding domain derived from human fibroblast growth factor-2 and its effect on osteoblast differentiation. Journal of Biomedical Materials Research - Part A, 2007, 83A, 970-979.	2.1	45
104	Basic fibroblast growth factor (FGF-2): The high molecular weight forms come of age. Journal of Cellular Biochemistry, 2007, 100, 1100-1108.	1.2	88
105	Molecular determinants of FGF-21 activityâ€"synergy and cross-talk with PPARγ signaling. Journal of Cellular Physiology, 2007, 210, 1-6.	2.0	168
106	Synectin/syndecan-4 regulate coronary arteriolar growth during development. Developmental Dynamics, 2007, 236, 2004-2010.	0.8	23
107	Purification and modification by polyethylene glycol of a new human basic fibroblast growth factor mutant-hbFGFSer25,87,92. Journal of Chromatography A, 2007, 1161, 51-55.	1.8	7
108	Increased angiogenesis and blood vessel maturation in acellular collagen–heparin scaffolds containing both FGF2 and VEGF. Biomaterials, 2007, 28, 1123-1131.	5.7	394
109	The zebrafish/tumor xenograft angiogenesis assay. Nature Protocols, 2007, 2, 2918-2923.	5.5	218
110	Vascular Response to Hypoxic Preconditioning in the Immature Brain. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 928-938.	2.4	74

#	Article	IF	CITATIONS
111	Intraluminal plugs in idiopathic and secondary organizing pneumonia: repair or remodelling?. Histopathology, 2007, 51, 622-630.	1.6	10
112	Paracrinicity: The Story of 30 Years of Cellular Pituitary Crosstalk. Journal of Neuroendocrinology, 2008, 20, 1-70.	1.2	181
113	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. British Journal of Haematology, 2007, 137, 560-568.	1.2	37
114	Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factorâ€2 (FGFâ€2). Journal of Thrombosis and Haemostasis, 2008, 6, 176-183.	1.9	202
115	Biomarkers for diet and cancer prevention research: potentials and challenges. Acta Pharmacologica Sinica, 2007, 28, 1262-1273.	2.8	46
116	Mechanical stress-initiated signal transduction in vascular smooth muscle cells in vitro and in vivo. Cellular Signalling, 2007, 19, 881-891.	1.7	126
117	Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Experimental Cell Research, 2007, 313, 3645-3657.	1.2	23
118	Role of the soluble pattern recognition receptor PTX3 in vascular biology. Journal of Cellular and Molecular Medicine, 2007, 11, 723-738.	1.6	166
119	Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. Journal of Cellular and Molecular Medicine, 2007, 11, 1384-1394.	1.6	87
120	Matrices and scaffolds for drug delivery in vascular tissue engineering. Advanced Drug Delivery Reviews, 2007, 59, 360-373.	6.6	77
121	Tumour vascularization: sprouting angiogenesis and beyond. Cancer and Metastasis Reviews, 2007, 26, 489-502.	2.7	464
122	Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis, 2007, 10, 149-166.	3.7	411
123	Immunohistochemical analysis of growth mechanisms in juvenile nasopharyngeal angiofibroma. European Archives of Oto-Rhino-Laryngology, 2007, 264, 389-394.	0.8	50
124	Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clinical and Experimental Metastasis, 2008, 25, 703-716.	1.7	36
125	The Increase in Retinal Cells Proliferation Induced by FGF2 is Mediated by Tyrosine and PI3 Kinases. Neurochemical Research, 2008, 33, 754-764.	1.6	6
126	Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis, 2008, 11, 53-62.	3.7	208
127	IL-1beta differently involved in IL-8 and FGF-2 release in crystalline silica-treated lung cell co-cultures. Particle and Fibre Toxicology, 2008, 5, 16.	2.8	31
128	Chemokine receptors and neurotrophic factors: Potential therapy against aids dementia?. Journal of Neuroscience Research, 2008, 86, 243-255.	1.3	22

#	Article	IF	CITATIONS
129	Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxiaâ€inducible factorâ€1 alpha. International Journal of Cancer, 2008, 122, 5-14.	2.3	71
130	Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance. Journal of Cellular Biochemistry, 2008, 103, 691-708.	1.2	36
131	HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HSâ€dependent responses. Journal of Cellular Biochemistry, 2008, 105, 1183-1193.	1.2	12
132	FGFâ€21/FGFâ€21 receptor interaction and activation is determined by βKlotho. Journal of Cellular Physiology, 2008, 215, 1-7.	2.0	296
133	Effects of FGF-2 release from a hydrogel polymer on bone mass and microarchitecture. Biomaterials, 2008, 29, 1593-1600.	5.7	48
134	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). International Journal of Radiation Oncology Biology Physics, 2008, 71, 79-86.	0.4	91
135	Regenerative cell therapy and pharmacotherapeutic intervention in heart failure. Netherlands Heart Journal, 2008, 16, 337-343.	0.3	4
136	Spheroid-based engineering of a human vasculature in mice. Nature Methods, 2008, 5, 439-445.	9.0	190
137	Human dermal fibroblast subpopulations; differential interactions with vascular endothelial cells in coculture: Nonsoluble factors in the extracellular matrix influence interactions. Wound Repair and Regeneration, 2008, 16, 300-309.	1.5	68
138	\hat{l}^2 2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. Journal of Thrombosis and Haemostasis, 2008, 6, 1215-1223.	1.9	44
139	Extracellular HSP70 blocks CD40Lâ€induced apoptosis and tubular formation in endothelial cells. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, S222-8.	1.4	5
140	Collagens, stromal cellâ€derived factorâ€1α and basic fibroblast growth factor increase cancer cell invasiveness in a hyaluronan hydrogel. Cell Proliferation, 2008, 41, 348-364.	2.4	18
141	JNK signaling pathway is required for bFGF-mediated surface cadherin downregulation on HUVEC. Experimental Cell Research, 2008, 314, 421-429.	1.2	24
142	Fibroblast Growth Factor 4 Gene Therapy for Chronic Ischemic Heart Disease. Trends in Cardiovascular Medicine, 2008, 18, 133-141.	2.3	18
143	Discovery of Brivanib Alaninate $((\langle i\rangle Sindol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazir A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215). Journal of Medicinal Chemistry, 2008, 51, 1976-1980.$	1-6 <u>-y</u> loxy)p	ropan-2-yl)2-
144	Transgenic Mouse Models of Angiogenesis and Lymphangiogenesis. International Review of Cell and Molecular Biology, 2008, 266, 1-35.	1.6	10
145	Structure of the Tandem Fibronectin Type 3 Domains of Neural Cell Adhesion Molecule. Journal of Molecular Biology, 2008, 377, 524-534.	2.0	37
146	Angiogenesis and growth factor modulation induced by alternagin C, a snake venom disintegrin-like, cysteine-rich protein on a rat skin wound model. Archives of Biochemistry and Biophysics, 2008, 479, 20-27.	1.4	18

#	Article	IF	Citations
147	Molecular mechanism of the inhibitory effect of KS-5 on bFGF-induced angiogenesis in vitro and in vivo. Cancer Letters, 2008, 263, 114-121.	3.2	11
148	The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway. Cancer Letters, 2008, 267, 67-74.	3.2	22
149	Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. European Journal of Cancer, 2008, 44, 151-159.	1.3	39
150	Microarray analysis reveals differences in expression of cell surface and extracellular matrix components during development of the trout ovary and testis. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2008, 3, 78-90.	0.4	10
151	Immunotherapy of Angiogenesis with DNA Vaccines. , 2008, , 451-460.		0
152	FGF-1: From Biology Through Engineering to Potential Medical Applications. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 91-135.	2.7	57
153	Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases. BioDrugs, 2008, 22, 37-44.	2.2	85
154	Oligosaccharides as anti-angiogenic agents. Expert Opinion on Biological Therapy, 2008, 8, 351-362.	1.4	18
155	Evidence That Heparin Saccharides Promote FGF2 Mitogenesis through Two Distinct Mechanisms. Journal of Biological Chemistry, 2008, 283, 13001-13008.	1.6	76
157	Temporally Expressed PDGF and FGF-2 Regulate Embryonic Coronary Artery Formation and Growth. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1237-1243.	1.1	39
158	Emerging Roles for the CD36 Scavenger Receptor as a Potential Therapeutic Target for Corneal Neovascularization. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 255-272.	0.6	8
159	Potent anti-angiogenic motifs within the Alzheimer \hat{l}^2 -amyloid peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 5-19.	1.4	15
160	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. Molecular Cancer Therapeutics, 2008, 7, 2405-2414.	1.9	8
161	Branching Morphogenesis. Circulation Research, 2008, 103, 784-795.	2.0	144
162	Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1. Journal of Biological Chemistry, 2008, 283, 2139-2146.	1.6	104
163	Effect of FGF-binding Protein 3 on Vascular Permeability. Journal of Biological Chemistry, 2008, 283, 28329-28337.	1.6	17
164	Fibroblast Growth Factor Receptor 2 Phosphorylation on Serine 779 Couples to 14-3-3 and Regulates Cell Survival and Proliferation. Molecular and Cellular Biology, 2008, 28, 3372-3385.	1.1	18
165	Direct Binding of Integrin $\hat{l}\pm\nu\hat{l}^23$ to FGF1 Plays a Role in FGF1 Signaling. Journal of Biological Chemistry, 2008, 283, 18066-18075.	1.6	127

#	Article	IF	CITATIONS
166	The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis. Annals of the Rheumatic Diseases, 2008, 67, 518-523.	0.5	95
167	Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3627-3632.	1.8	100
168	Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia. Molecular Therapy, 2008, 16, 972-978.	3.7	294
169	An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. Development (Cambridge), 2008, 135, 3599-3610.	1.2	132
170	Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood, 2008, 111, 2036-2045.	0.6	143
171	Constitutive expression of IL- $12R\hat{l}^2$ 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759.	0.6	38
172	Pulmonary Biomarkers of Bronchopulmonary Dysplasia. Biomarker Insights, 2008, 3, BMI.S834.	1.0	56
173	Exon III Splicing of Fibroblast Growth Factor Receptor 1 Is Modulated by Growth Factors and Cyclin D1. Pancreas, 2008, 37, 159-164.	0.5	11
174	Remission of Infantile Generalized Myofibromatosis After Interferon Alpha Therapy. Journal of Pediatric Hematology/Oncology, 2008, 30, 179-181.	0.3	15
175	Fibroblast growth factor regulation of neovascularization. Current Opinion in Hematology, 2008, 15, 215-220.	1.2	259
176	Effects of 30 min of aerobic exercise on gene expression in human neutrophils. Journal of Applied Physiology, 2008, 104, 236-243.	1.2	108
177	Tumor Angiogenesis., 2008,, 241-251.		2
178	The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Research, 2008, 2008, 1-12.	1.1	22
179	Transforming growth factor-beta 1 (tgf-&946;1) induces angiogenesis through vascular endothelial growth factor (vegf)-mediated apoptosis. Nature Precedings, 2008, , .	0.1	1
180	Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. Anais Da Academia Brasileira De Ciencias, 2009, 81, 409-429.	0.3	201
181	The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thrombosis and Haemostasis, 2009, 102, 544-554.	1.8	98
182	Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Frontiers in Bioscience - Landmark, 2009, Volume, 2248.	3.0	28
183	A distinct role for secreted fibroblast growth factor-binding proteins in development. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8585-8590.	3.3	25

#	Article	IF	CITATIONS
184	Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway. Journal of Biological Chemistry, 2009, 284, 25854-25866.	1.6	119
185	G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, Alters <i>In vitro</i> Endothelial Cell Growth and Tubular Morphogenesis. Clinical Cancer Research, 2009, 15, 2797-2807.	3.2	20
186	Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. Twin Research and Human Genetics, 2009, 12, 269-275.	0.3	8
187	Plasma–Fibroblast Gel as Scaffold for Islet Transplantation. Tissue Engineering - Part A, 2009, 15, 569-577.	1.6	27
188	Branching Morphogenesis. Circulation Research, 2009, 104, e21.	2.0	19
189	Peptides Targeting Angiogenesis Related Growth Factor Receptors. Current Pharmaceutical Design, 2009, 15, 2414-2429.	0.9	39
190	Strategies to improve drug delivery in bladder cancer therapy. Expert Opinion on Drug Delivery, 2009, 6, 727-744.	2.4	19
191	Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands. Current Drug Targets, 2009, 10, 632-644.	1.0	51
192	Current thoughts on angiogenesis. Journal of Wound Care, 2009, 18, 12-15.	0.5	5
193	Paths of FGFR-driven tumorigenesis. Cell Cycle, 2009, 8, 580-588.	1.3	141
194	Local Gene Transfer and Expression Following Intramuscular Administration of FGF-1 Plasmid DNA in Patients With Critical Limb Ischemia. Molecular Therapy, 2009, 17, 914-921.	3.7	56
195	Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors, 2009, 9, 6471-6503.	2.1	17
196	Satellite cell-mediated angiogenesis in vitro coincides with a functional hypoxia-inducible factor pathway. American Journal of Physiology - Cell Physiology, 2009, 296, C1321-C1328.	2.1	107
197	Molecular Pathology of Neuro-AIDS (CNS-HIV). International Journal of Molecular Sciences, 2009, 10, 1045-1063.	1.8	67
198	FGF2 is crucial for the development of bovine luteal endothelial networks in vitro. Reproduction, 2009, 138, 581-588.	1.1	42
199	Prostaglandin E 2 Primes the Angiogenic Switch via a Synergic Interaction With the Fibroblast Growth Factor-2 Pathway. Circulation Research, 2009, 105, 657-666.	2.0	48
200	Angiogenesis and vascular function in the ovary. Reproduction, 2009, 138, 869-881.	1.1	220
201	Identification of Protein Kinase D2 as a Pivotal Regulator of Endothelial Cell Proliferation, Migration, and Angiogenesis. Journal of Biological Chemistry, 2009, 284, 799-806.	1.6	48

#	Article	IF	CITATIONS
202	Specific inhibition of FGF-2 signaling with 2-O-sulfated octasaccharides of heparan sulfate. Glycobiology, 2009, 19, 644-654.	1.3	30
203	Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology, 2009, 34, 353-357.	1.3	95
204	The functional role of cell adhesion molecules in tumor angiogenesis. Seminars in Cancer Biology, 2009, 19, 298-309.	4.3	77
205	A proâ€inflammatory signature mediates FGF2â€induced angiogenesis. Journal of Cellular and Molecular Medicine, 2009, 13, 2083-2108.	1.6	66
206	Fibroblast growth factor 2â€induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. Journal of Cellular and Molecular Medicine, 2009, 13, 2061-2068.	1.6	58
207	Fibroblast growth factor receptor†phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. Journal of Cellular and Molecular Medicine, 2009, 13, 1489-1498.	1.6	11
208	Fibroblast growth factor 2â€antagonist activity of a longâ€pentraxin 3â€derived antiâ€angiogenic pentapeptide. Journal of Cellular and Molecular Medicine, 2010, 14, 2109-2121.	1.6	46
209	Behavior of rat periodontal ligament cells on fibroblast growth factorâ€2â€immobilized titanium surfaces treated by plasma modification. Journal of Biomedical Materials Research - Part A, 2009, 91A, 69-75.	2.1	7
210	FGFâ€8b induces growth and rich vascularization in an orthotopic PCâ€3 model of prostate cancer. Journal of Cellular Biochemistry, 2009, 107, 769-784.	1.2	27
211	Different roles of N―and C―termini in the functional activity of FGF21. Journal of Cellular Physiology, 2009, 219, 227-234.	2.0	114
212	Transforming growth factor $\hat{\epsilon}$ beta 1 (TGF $\hat{\epsilon}$ 1) induces angiogenesis through vascular endothelial growth factor (VEGF) $\hat{\epsilon}$ mediated apoptosis. Journal of Cellular Physiology, 2009, 219, 449-458.	2.0	273
213	Cytotoxicity and antiangiogenesis by fibroblast growth factor 2–targeted Adâ€₹K cancer gene therapy. Laryngoscope, 2009, 119, 665-674.	1.1	14
214	Stem cell antigenâ€1 ⁺ cellâ€based bone morphogenetic proteinâ€4 gene transfer strategy in mice failed to promote endosteal bone formation. Journal of Gene Medicine, 2009, 11, 877-888.	1.4	6
215	Localization patterns of fibroblast growth factor 1 and its receptors FGFR1 and FGFR2 in postnatal mouse retina. Cell and Tissue Research, 2009, 336, 423-438.	1.5	23
216	Expression of Growth Factors in Endotheliocytes in Vascular Malformations. Bulletin of Experimental Biology and Medicine, 2009, 147, 366-370.	0.3	24
217	Sulfated glyco-block copolymers with specific receptor and growth factor binding to support cell adhesion and proliferation. Biomaterials, 2009, 30, 1026-1035.	5.7	21
218	Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding. Cytotechnology, 2009, 60, 33-44.	0.7	9
219	InÂvitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering. Journal of Materials Science: Materials in Medicine, 2009, 20, 45-50.	1.7	33

#	Article	IF	CITATIONS
220	Mediators of ocular angiogenesis. Journal of Genetics, 2009, 88, 495-515.	0.4	153
221	Fibroblast growth factor 21: an overview from a clinical perspective. Cellular and Molecular Life Sciences, 2009, 66, 2067-2073.	2.4	39
222	Fibroblast Growth Factor-2 Overexpression in Transplanted Neural Progenitors Promotes Perivascular Cluster Formation with a Neurogenic Potential. Stem Cells, 2009, 27, 1309-1317.	1.4	25
223	Stilbene glycosides are natural product inhibitors of FGF-2-induced angiogenesis. BMC Cell Biology, 2009, 10, 30.	3.0	17
224	rAAV-mediated overexpression of FGF-2 promotes cell proliferation, survival, and α-SMA expression in human meniscal lesions. Gene Therapy, 2009, 16, 1363-1372.	2.3	56
225	The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery, 2009, 8, 235-253.	21.5	1,548
226	Overexpression in Escherichia coli and purification of human fibroblast growth factor (FGF-2). Biochemistry (Moscow), 2009, 74, 221-225.	0.7	32
227	Basic fibroblast growth factor stimulates epithelial cell growth and epithelial wound healing in canine corneas. Veterinary Ophthalmology, 2009, 12, 170-175.	0.6	19
228	Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion, 2009, 49, 771-778.	0.8	153
229	Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate. Carbohydrate Research, 2009, 344, 2394-2398.	1.1	8
230	Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: Correlation with clinicopathological features and prognosis. Pathology Research and Practice, 2009, 205, 542-550.	1.0	14
231	Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling. Chemical Reviews, 2009, 109, 3099-3124.	23.0	104
232	A Molecular Mimic of Phosphorylated Prolactin (S179D PRL) Secreted by Eukaryotic Cells Has a Conformation with an Increased Positive Surface Charge Compared to That of Unmodified Prolactin. Biochemistry, 2009, 48, 6887-6897.	1.2	5
233	Subconjunctival Injection of Bevacizumab (Avastin) on Corneal Neovascularization in Different Rabbit Models of Corneal Angiogenesis., 2009, 50, 1659.		74
234	Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochemical and Biophysical Research Communications, 2009, 379, 206-211.	1.0	63
235	FGFR-1 is required by epicardium-derived cells for myocardial invasion and correct coronary vascular lineage differentiation. Developmental Biology, 2009, 328, 148-159.	0.9	50
236	Head and Neck Squamous cell Carcinoma Targeted Chemosensitization. Otolaryngology - Head and Neck Surgery, 2009, 141, 177-183.	1.1	5
237	Autologous transplantation of EPCs encoding FGF1 gene promotes neovascularization in a porcine model of chronic myocardial ischemia. International Journal of Cardiology, 2009, 135, 223-232.	0.8	31

#	ARTICLE	IF	CITATIONS
238	Angiogenesis in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 46-49.	1.4	12
239	Oxidative Stress, Inflammation and Angiogenesis in the Metabolic Syndrome. , 2009, , .		20
240	Structural interactomics: informatics approaches to aid the interpretation of genetic variation and the development of novel therapeutics. Molecular BioSystems, 2009, 5, 1456.	2.9	8
241	Angiogenic activity in sera of patients with systemic lupus erythematosus. Lupus, 2009, 18, 705-712.	0.8	8
242	Whole brain radiotherapy with radiosensitizer for brain metastases. Journal of Experimental and Clinical Cancer Research, 2009, 28, 1.	3.5	73
244	Pathophysiology and genetic factors in moyamoya disease. Neurosurgical Focus, 2009, 26, E4.	1.0	115
245	Regenerative Therapy in Peripheral Artery Disease. Cardiovascular Therapeutics, 2009, 27, 289-304.	1.1	38
246	Inflammatory cells andÂchemokines sustain FGF2-induced angiogenesis. European Cytokine Network, 2009, 20, 39-50.	1.1	114
247	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523.	3.9	177
248	HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood, 2009, 113, 5669-5679.	0.6	141
249	Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis. Blood, 2009, 113, 488-497.	0.6	115
250	Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy. Journal of Thoracic Oncology, 2009, 4, 463-471.	0.5	29
251	Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival. Journal of Thoracic Oncology, 2009, 4, 578-585.	0.5	64
252	Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides. Current Pharmaceutical Design, 2009, 15, 3577-3589.	0.9	33
253	The Role of Fibroblast Growth Factors in Tumor Growth. Current Cancer Drug Targets, 2009, 9, 639-651.	0.8	305
254	Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncology Reports, 2010, 24, 457-63.	1.2	24
255	Angiogenesis as a therapeutic target in urothelial carcinoma. Anti-Cancer Drugs, 2010, 21, 890-896.	0.7	20
256	FGF-2 is overexpressed in myoepithelial cells of carcinoma ex-pleomorphic adenoma in situ structures. Oncology Reports, 2010, 24, 155-60.	1.2	14

#	Article	IF	CITATIONS
257	Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood, 2010, 115, 3843-3851.	0.6	75
258	Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell–lymphotoxin-dependent pathway. Blood, 2010, 115, 4725-4733.	0.6	136
259	Synthesis of N-Heteroaroyl Aminosaccharide Derivatives as Fibroblast Growth Factor 2 Signaling Modulators. Chemical and Pharmaceutical Bulletin, 2010, 58, 1210-1215.	0.6	2
260	VEGF and TNF up-regulate, NSAID down-regulate SOX18 protein level in HUVEC. Open Life Sciences, 2010, 5, 427-434.	0.6	1
261	Distribution of fibroblast growth factor-2 (FGF-2) within model excisional wounds following topical application. Journal of Pharmacy and Pharmacology, 2010, 61, 193-200.	1.2	7
262	The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials, 2010, 31, 7012-7020.	5.7	264
263	Fgfbp1 Is Essential for the Cellular Survival during Zebrafish Embryogenesis. Molecules and Cells, 2010, 29, 501-508.	1.0	10
264	Osteogenic Responses to Different Concentrations/Ratios of BMP-2 and bFGF in Bone Formation. Annals of Biomedical Engineering, 2010, 38, 77-87.	1.3	78
265	IGF-1 and BMP-2 Induces Differentiation of Adipose-Derived Mesenchymal Stem Cells into Chondrocytes-Like Cells. Annals of Biomedical Engineering, 2010, 38, 1647-1654.	1.3	98
266	Chitosan-Alginate Scaffold Culture System for Hepatocellular Carcinoma Increases Malignancy and Drug Resistance. Pharmaceutical Research, 2010, 27, 1939-1948.	1.7	86
267	Multimodal release of transforming growth factor- \hat{l}^21 and the BB isoform of platelet derived growth factor from PEGylated fibrin gels. Journal of Controlled Release, 2010, 147, 180-186.	4.8	63
268	Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 103-120.	1.9	197
269	Thyroid hormone and angiogenesis. Vascular Pharmacology, 2010, 52, 142-145.	1.0	112
270	Regulation of angiogenesis by a small GTPase Rap1. Vascular Pharmacology, 2010, 53, 1-10.	1.0	36
271	Spindle cells from acquired immune deficiency syndromeâ€associated Kaposi's sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factorâ€2. International Journal of Cancer, 2010, 127, 2487-2489.	2.3	1
272	Embryonic coronary vasculogenesis and angiogenesis are regulated by interactions between multiple FGFs and VEGF and are influenced by mesenchymal stem cells. Developmental Dynamics, 2010, 239, 3182-3191.	0.8	25
273	Angiogenesis and the persistence of inflammation in a rat model of proliferative synovitis. Arthritis and Rheumatism, 2010, 62, 1890-1898.	6.7	33
274	FGF-2 and VEGF functionalization of starPEG–heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. Biomaterials, 2010, 31, 7985-7994.	5.7	187

#	Article	IF	CITATIONS
275	Dendrimer-based tumor cell targeting of fibroblast growth factor-1. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 700-703.	1.0	44
276	The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials, 2010, 31, 7226-7238.	5.7	56
277	Effects on $\langle i \rangle$ in vitro $\langle j \rangle$ and $\langle i \rangle$ in vivo $\langle j \rangle$ angiogenesis induced by small peptides carrying adhesion sequences. Journal of Peptide Science, 2010, 16, 349-357.	0.8	26
278	Alzheimer's βâ€amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFRâ€2. Journal of Neurochemistry, 2010, 112, 66-76.	2.1	84
279	Study of growth factors and receptors in carcinoma ex pleomorphic adenoma. Journal of Oral Pathology and Medicine, 2010, 39, 540-7.	1.4	19
280	Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Science, 2010, 101, 1212-1218.	1.7	24
281	Involvement of fibroblast growth factor 18 in dedifferentiation of cultured human chondrocytes. Cell Proliferation, 2010, 43, 67-76.	2.4	25
282	Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy, 2010, 17, 763-769.	2.3	49
283	Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer, 2010, 10, 116-129.	12.8	2,172
284	Anti-angiogenesis therapies: their potential in cancer management. OncoTargets and Therapy, 2010, 3, 69.	1.0	39
285	Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals, 2010, 3, 1241-1278.	1.7	30
286	Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. Oncology Reports, 2010, 23, 701-8.	1.2	5
287	Multiple Beneficial Health Effects of Natural Alkylglycerols from Shark Liver Oil. Marine Drugs, 2010, 8, 2175-2184.	2.2	59
288	FGF-2, TGF \hat{I}^2 -1, PDGF-A and respective receptors expression in pleomorphic adenoma myoepithelial cells: an in vivo and in vitro study. Journal of Applied Oral Science, 2010, 18, 83-91.	0.7	18
289	Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts. Clinical Cancer Research, 2010, 16, 5750-5758.	3.2	66
290	Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. Clinical Cancer Research, 2010, 16, 390-397.	3.2	98
291	Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition. Toxicologic Pathology, 2010, 38, 267-279.	0.9	15
292	Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1. Molecular Cancer Therapeutics, 2010, 9, 3244-3253.	1.9	28

#	Article	IF	CITATIONS
293	Roles of Fibroblast Growth Factor Receptors in Carcinogenesis. Molecular Cancer Research, 2010, 8, 1439-1452.	1.5	263
294	Placental development during early pregnancy in sheep: vascular growth and expression of angiogenic factors in maternal placenta. Reproduction, 2010, 140, 165-174.	1.1	78
295	Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells. Growth Factors, 2010, 28, 256-267.	0.5	10
296	Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration. Journal of Tissue Engineering, 2010, 1, 218142.	2.3	457
297	Mechanisms of Ocular Angiogenesis and Its Molecular Mediators. Developments in Ophthalmology, 2010, 46, 4-20.	0.1	63
298	Heparan Sulfate Domain Organization and Sulfation Modulate FGF-induced Cell Signaling. Journal of Biological Chemistry, 2010, 285, 26842-26851.	1.6	62
299	The Angiogenic Inhibitor Long Pentraxin PTX3 Forms an Asymmetric Octamer with Two Binding Sites for FGF2. Journal of Biological Chemistry, 2010, 285, 17681-17692.	1.6	106
300	Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer. Cancer Research, 2010, 70, 2644-2654.	0.4	84
301	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. Cardiovascular Research, 2010, 85, 649-660.	1.8	66
302	Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 311-319.	3.2	157
303	The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases. Molecular Cancer Therapeutics, 2010, 9, 369-378.	1.9	72
304	Targeting AAC-11 in cancer therapy. Expert Opinion on Therapeutic Targets, 2010, 14, 57-65.	1.5	16
305	S100A13 is a new angiogenic marker in human melanoma. Modern Pathology, 2010, 23, 804-813.	2.9	61
306	FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. Islets, 2010, 2, 247-251.	0.9	25
307	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opinion on Pharmacotherapy, 2010, 11, 2187-2198.	0.9	12
308	Development of Functional Fibrous Matrices for the Controlled Release of Basic Fibroblast Growth Factor to Improve Therapeutic Angiogenesis. Tissue Engineering - Part A, 2010, 16, 2999-3010.	1.6	31
309	Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer, 2010, 70, 233-246.	0.9	15
310	Endothelial Heparan Sulfate in Angiogenesis. Progress in Molecular Biology and Translational Science, 2010, 93, 179-212.	0.9	70

#	ARTICLE	IF	CITATIONS
311	Cellular Proliferation, Apoptosis and Angiogenesis: Molecular Targets for Nutritional Preemption of Cancer. Seminars in Oncology, 2010, 37, 243-257.	0.8	29
312	Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering. Current Medicinal Chemistry, 2010, 17, 3944-3967.	1.2	107
313	Effects of Fibroblast Growth Factor-2 on the Expression and Regulation of Chemokines in Human Dental Pulp Cells. Journal of Endodontics, 2010, 36, 1824-1830.	1.4	71
314	Mitochondria as targets in angiogenesis inhibition. Molecular Aspects of Medicine, 2010, 31, 113-131.	2.7	26
315	Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biology, 2010, 29, 442-452.	1.5	114
316	In vivo modulation of angiogenesis by beta 2 glycoprotein I. Journal of Autoimmunity, 2010, 35, 232-240.	3.0	23
317	Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochemical and Biophysical Research Communications, 2010, 394, 767-773.	1.0	22
318	Use of microarray analysis to study gene expression in the avian epiphyseal growth plate. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2010, 5, 12-23.	0.4	9
319	Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice. Peptides, 2010, 31, 850-864.	1.2	43
320	Effect of Human S100A13 Gene Silencing on FGF-1 Transportation in Human Endothelial Cells. Journal of the Formosan Medical Association, 2010, 109, 632-640.	0.8	7
321	Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 819-826.	0.7	37
322	Binding region and interaction properties of sulfoquinovosylacylglycerol (SQAG) with human vascular endothelial growth factor 165 revealed by biosensor-based assays. MedChemComm, 2011, 2, 1188.	3.5	7
323	Fibroblast growth factors and their receptors in cancer. Biochemical Journal, 2011, 437, 199-213.	1.7	472
324	Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2011, 29, 325-337.	0.6	66
325	Brivanib alaninate for cancer. Expert Opinion on Investigational Drugs, 2011, 20, 577-586.	1.9	39
326	Characterization and modulation of fibroblast/endothelial cell co-cultures for the <i>in vitro </i> preformation of three-dimensional tubular networks. Cell Biology International, 2011, 35, 1097-1110.	1.4	37
327	Transcriptional profiling of angiogenesis activities of calycosin in zebrafish. Molecular BioSystems, 2011, 7, 3112.	2.9	29
328	Inflammatory Corneal Neovascularization: Etiopathogenesis. Seminars in Ophthalmology, 2011, 26, 235-245.	0.8	64

#	Article	IF	CITATIONS
329	Induced Migration of Dental Pulp Stem Cells for in vivo Pulp Regeneration. Journal of Dental Research, 2011, 90, 1013-1018.	2.5	165
330	Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clinical Cancer Research, 2011, 17, 6130-6139.	3.2	262
331	Extracellular Matrix Degradation. , 2011, , .		10
332	Theoretical and Clinical Considerations for Autologous Blood Preparations: Platelet-Rich Plasma, Fibrin Sealants, and Plasma-Rich Growth Factors. Clinical Advances in Periodontics, 2011, 1, 142-153.	0.4	9
333	Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer. Cancer Treatment Reviews, 2011, 37, 611-617.	3.4	26
334	Which alkylglycerols from shark liver oil have anti-tumour activities?. Biochimie, 2011, 93, 1-3.	1.3	31
335	Dilatation of preexisting venous collateral pathways as a possible treatment option in patients with Budd–Chiari Syndrom. European Journal of Radiology Extra, 2011, 78, e39-e42.	0.1	1
336	Prevention of FGF-2-induced angiogenesis by scopoletin, a coumarin compound isolated from Erycibe obtusifolia Benth, and its mechanism of action. International Immunopharmacology, 2011, 11, 2007-2016.	1.7	39
337	Neurotrophic signaling molecules associated with cholinergic damage in young and aged rats: Environmental enrichment as potential therapeutic agent. Neurobiology of Aging, 2011, 32, 470-485.	1.5	30
338	Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research, 2011, 13, 221.	2.2	185
339	Embryonic Stem Cells as a Model System to Elucidate Early Events in Cardiac Specification and Determination. , $2011, \dots$		0
340	FGF-dependent regulation of VEGF receptor 2 expression in mice. Journal of Clinical Investigation, 2011, 121, 2668-2678.	3.9	156
341	New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Therapeutics and Clinical Risk Management, 2011, 7, 429.	0.9	11
342	Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging, 2011, 3, 920-933.	1.4	110
343	Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. OncoTargets and Therapy, 2011, 4, 43.	1.0	47
344	The role of angiogenic growth factors in organogenesis. International Journal of Developmental Biology, 2011, 55, 365-375.	0.3	49
345	The VEGF-regulated transcription factor HLX controls the expression of guidance cues and negatively regulates sprouting of endothelial cells. Blood, 2011, 117, 2735-2744.	0.6	30
346	A novel combined conjugate vaccine: Enhanced immunogenicity of bFGF with CRM197 as a carrier protein. Molecular Medicine Reports, 2011, 4, 857-63.	1.1	5

#	Article	IF	CITATIONS
347	Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease. Physiological Genomics, 2011, 43, 87-98.	1.0	15
348	Novel approach to ischemic skin ulcer in systemic lupus erythematosus: Therapeutic angiogenesis by controlledâ€release basic fibroblast growth factor. Geriatrics and Gerontology International, 2011, 11, 527-530.	0.7	5
349	Fibroblast and Vascular Endothelial Growth Factor Coating of Decellularized Vascular Grafts Stimulates Undesired Giant Cells and Graft Encapsulation in a Rat Model. Artificial Organs, 2011, 35, E1-E10.	1.0	11
350	Repair of bone defects around dental implants with bone morphogenetic protein/fibroblast growth factor-loaded porous calcium phosphate cement: a pilot study in a canine model. Clinical Oral Implants Research, 2011, 22, 173-181.	1.9	27
351	Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene, 2011, 30, 1183-1193.	2.6	117
352	Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. Journal of Controlled Release, 2011, 156, 28-36.	4.8	116
353	The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Seminars in Cancer Biology, 2011, 21, 35-43.	4.3	322
354	The epicardium in cardiac repair: From the stem cell view. , 2011, 129, 82-96.		80
355	The neuronal influence on tumor progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 105-118.	3.3	108
356	Immortalization of swine umbilical vein endothelial cells (SUVECs) with the simian virus 40 largeâ€₹ antigen. Molecular Reproduction and Development, 2011, 78, 597-610.	1.0	11
357	The characterization of protein release from sericin film in the presence of an enzyme: Towards fibroblast growth factor-2 delivery. International Journal of Pharmaceutics, 2011, 414, 193-202.	2.6	16
358	Expression of angiogenic basic fibroblast growth factor, platelet derived growth factor, thrombospondin-1 and their receptors at the porcine maternal-fetal interface. Reproductive Biology and Endocrinology, 2011, 9, 5.	1.4	37
359	Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. Journal of Translational Medicine, 2011, 9, 104.	1.8	17
360	Viruses as key regulators of angiogenesis. Reviews in Medical Virology, 2011, 21, 181-200.	3.9	12
361	Regulation of nonâ€classical FGF1 release and FGFâ€dependent cell transformation by CBF1â€mediated notch signaling. Journal of Cellular Physiology, 2011, 226, 3064-3075.	2.0	17
362	Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer, 2011, 117, 3889-3899.	2.0	49
363	Immobilization of Ag nanoparticles/FGFâ€2 on a modified titanium implant surface and improved human gingival fibroblasts behavior. Journal of Biomedical Materials Research - Part A, 2011, 98A, 274-286.	2.1	51
364	Gene therapy in the treatment of peripheral arterial disease. British Journal of Surgery, 2011, 99, 6-15.	0.1	38

#	Article	IF	CITATIONS
365	Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size. Clinical Lung Cancer, 2011, 12, 106-115.	1.1	23
366	ls VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology, 2011, 79, 103-111.	2.0	31
367	Release kinetics and cellular profiles for bFGF-loaded electrospun fibers: Effect of the conjugation density and molecular weight of heparin. Polymer, 2011, 52, 3357-3367.	1.8	24
368	The role of serum basic fibroblast growth factor, estradiol and urine basic fibroblast growth factor in differentiating infantile haemangiomas from vascular malformations. Phlebology, 2011, 26, 191-196.	0.6	10
369	Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species., 2011, 2011, 2447-50.		4
370	Angiogenesis and parasitic helminth-associated neovascularization. Parasitology, 2011, 138, 426-439.	0.7	28
371	Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer. Molecular Cancer Therapeutics, 2011, 10, 2157-2167.	1.9	125
372	Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 1607-1618.	1.1	14
373	Growth Factor Mediated Signaling in Pancreatic Pathogenesis. Cancers, 2011, 3, 841-871.	1.7	24
374	Role of the Cytoskeleton in Formation and Maintenance of Angiogenic Sprouts. Journal of Vascular Research, 2011, 48, 369-385.	0.6	83
375	Angiomotin-like2 Gene (amotl2) Is Required for Migration and Proliferation of Endothelial Cells during Angiogenesis. Journal of Biological Chemistry, 2011, 286, 41095-41104.	1.6	72
376	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormone–Regulated Tumors. Molecular Cancer Therapeutics, 2011, 10, 1600-1610.	1.9	53
377	Antitumor Activity of a Recombinant Soluble Ectodomain of Mutant Human Fibroblast Growth Factor Receptor-2 Illc. Molecular Cancer Therapeutics, 2011, 10, 1656-1666.	1.9	6
378	Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 829-846.	1.5	48
379	Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke. Neurological Research, 2011, 33, 675-680.	0.6	39
380	Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor. Journal of Cell Science, 2011, 124, 3106-3117.	1.2	23
381	Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis. Cardiovascular Research, 2011, 89, 436-445.	1.8	25
382	Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition. Clinical Cancer Research, 2011, 17, 5299-5310.	3.2	124

#	Article	IF	CITATIONS
383	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. Journal of Investigative Dermatology, 2011, 131, 2087-2095.	0.3	70
384	MicroRNA-16 and MicroRNA-424 Regulate Cell-Autonomous Angiogenic Functions in Endothelial Cells via Targeting Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2595-2606.	1.1	227
385	Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomarkers, 2011, 7, 141-151.	0.8	5
386	Pathogen Recognition by the Long Pentraxin PTX3. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	67
387	The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO Journal, 2012, 31, 3309-3322.	3.5	32
388	Chronic hypoxia and VEGF differentially modulate abundance and organization of myosin heavy chain isoforms in fetal and adult ovine arteries. American Journal of Physiology - Cell Physiology, 2012, 303, C1090-C1103.	2.1	25
389	Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-21.	3.0	133
390	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 696-703.	1.1	69
391	Fibroblast growth factor 2 is a key determinant of vascular sprouting during bovine luteal angiogenesis. Reproduction, 2012, 143, 35-43.	1.1	41
393	The Thymidine Phosphorylase Inhibitor 5′- <i>O</i> -Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist. Molecular Cancer Therapeutics, 2012, 11, 817-829.	1.9	21
394	Regenerative therapy and tissue engineering for the treatment of end-stage cardiac failure. Biomatter, 2012, 2, 1-14.	2.6	45
395	Implanted neonatal human dermal fibroblasts influence the recruitment of endothelial cells in mice. Biomatter, 2012, 2, 43-52.	2.6	14
396	Emerging techniques to treat corneal neovascularisation. Eye, 2012, 26, 2-12.	1.1	36
397	Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species. Journal of the Royal Society Interface, 2012, 9, 147-157.	1.5	164
398	Sciatic nerve grafting and inoculation of FGF-2 promotes improvement of motor behavior and fiber regrowth in rats with spinal cord transection. Restorative Neurology and Neuroscience, 2012, 30, 265-275.	0.4	30
399	Regeneration of Tracheal Epithelium Using a Collagen Vitrigelâ€"Sponge Scaffold Containing Basic Fibroblast Growth Factor. Annals of Otology, Rhinology and Laryngology, 2012, 121, 261-268.	0.6	26
400	New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. Future Oncology, 2012, 8, 559-573.	1.1	8
401	Related Transcriptional Enhancer Factor 1 Increases Endothelial-Dependent Microvascular Relaxation and Proliferation. Journal of Vascular Research, 2012, 49, 249-259.	0.6	10

#	Article	IF	CITATIONS
402	Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer. Oncologist, 2012, 17, 212-219.	1.9	47
403	Signaling Required for Blood Vessel Maintenance: Molecular Basis and Pathological Manifestations. International Journal of Vascular Medicine, 2012, 2012, 1-15.	0.4	55
404	The Role of Vascular Endothelial Growth Factors and Fibroblast Growth Factors in Angiogenesis during Otitis Media. Audiology and Neuro-Otology, 2012, 17, 148-154.	0.6	13
405	Development and Validation of an Automated High-Throughput System for Zebrafish In Vivo Screenings. PLoS ONE, 2012, 7, e36690.	1.1	79
406	Fibroblast Growth Factor-2 Is Required for Vasa Vasorum Plexus Stability in Hypercholesterolemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2644-2651.	1.1	23
407	The tumor microenvironment in hepatocellular carcinoma (Review). International Journal of Oncology, 2012, 40, 1733-47.	1.4	111
408	Patents Review in siRNA Delivery for Pulmonary Disorders. Recent Patents on Drug Delivery and Formulation, 2012, 6, 45-65.	2.1	5
409	Synthesis of Disaccharides Containing 6-Deoxy-a-L-talose as Potential Heparan Sulfate Mimetics. Molecules, 2012, 17, 9790-9802.	1.7	8
410	Fibroblast Growth Factor 2â€"A Predictor of Outcome for Patients Irradiated for Stage II-III Nonâ€"Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 442-447.	0.4	17
411	Creating 3D Angiogenic Growth Factor Gradients in Fibrous Constructs to Guide Fast Angiogenesis. Biomacromolecules, 2012, 13, 3262-3271.	2.6	44
412	Substrate-Immobilized HIV-1 Tat Drives VEGFR2∫î± ⟨sub⟩v⟨ sub⟩ β ⟨sub⟩3⟨ sub⟩ â€"Integrin Complex Formation and Polarization in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e25-34.	1.1	15
413	Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine, 2012, 106, 473-492.	1.3	8
414	Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 114, 215-222.	0.2	24
415	Role of the Nuclear Receptor Coactivator AlB1/SRC-3 in Angiogenesis and Wound Healing. American Journal of Pathology, 2012, 180, 1474-1484.	1.9	20
416	Osteostatin improves the osteogenic activity of fibroblast growth factor-2 immobilized in Si-doped hydroxyapatite in osteoblastic cells. Acta Biomaterialia, 2012, 8, 2770-2777.	4.1	40
417	The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. Journal of the American Academy of Dermatology, 2012, 67, 194.e1-194.e8.	0.6	7 5
418	Effects of FGF-2 on human adipose tissue derived adult stem cells morphology and chondrogenesis enhancement in Transwell culture. Biochemical and Biophysical Research Communications, 2012, 424, 234-238.	1.0	46
419	Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Letters, 2012, 321, 101-109.	3.2	8

#	Article	IF	CITATIONS
420	A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts. Molecular Cancer Therapeutics, 2012, 11, 864-872.	1.9	55
421	Role of fibroblast growth factor signaling in vascular formation and maintenance: orchestrating signaling networks as an integrated system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2012, 4, 615-629.	6.6	12
422	HSULF-1 inhibits ERK and AKT signaling and decreases cell viability in vitro in human lung epithelial cells. Respiratory Research, 2012, 13, 69.	1.4	30
423	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Journal of Ovarian Research, 2012, 5, 23.	1.3	29
424	Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clinical Cancer Research, 2012, 18, 1855-1862.	3.2	371
425	<scp>AL</scp> 3810, a multiâ€tyrosine kinase inhibitor, exhibits potent antiâ€angiogenic and antiâ€tumour activity <i>via</i> targeting <scp>VEGFR</scp> , <scp> FGFR</scp> and <scp>PDGFR</scp> . Journal of Cellular and Molecular Medicine, 2012, 16, 2321-2330.	1.6	29
426	An Investigation of Growth Factors and Lactoferrin in Naturally Occurring Ovine Pulmonary Adenomatosis. Journal of Comparative Pathology, 2012, 147, 441-451.	0.1	10
427	Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions. Critical Reviews in Oncology/Hematology, 2012, 84, 47-58.	2.0	37
428	Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2012, 84, 149-160.	2.0	64
429	Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids, 2012, 43, 2203-2230.	1.2	54
430	DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nature Communications, 2012, 3, 1296.	5.8	52
431	Effects of Pien Tze Huang (片仔癀) on angiogenesis in vivo and in vitro. Chinese Journal of Integrative Medicine, 2012, 18, 431-436.	0.7	35
432	Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Medical Oncology, 2012, 29, 3119-3124.	1.2	12
433	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clinical and Translational Oncology, 2012, 14, 564-574.	1.2	12
434	Tissue Engineering in Drug Delivery. , 2012, , 533-568.		1
435	Serous Effusions., 2012,,.		9
436	Proteoglycans. Methods in Molecular Biology, 2012, 836, vii-viii.	0.4	2
437	Selection of Clinically useful Angiogenesis-Related Biomarkers: An Update. International Journal of Biological Markers, 2012, 27, 65-81.	0.7	0

#	Article	IF	CITATIONS
438	Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. International Journal of Cancer, 2012, 131, 1260-1266.	2.3	46
439	Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer, 2012, 118, 3455-3467.	2.0	67
440	Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Investigational New Drugs, 2012, 30, 1261-1269.	1.2	21
441	FGF Receptor Inhibitors: Role in Cancer Therapy. Current Oncology Reports, 2012, 14, 111-119.	1.8	51
442	c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis, 2012, 15, 187-197.	3.7	31
443	Silicate bioceramics induce angiogenesis during bone regeneration. Acta Biomaterialia, 2012, 8, 341-349.	4.1	240
444	Importance of Fibroblast Growth Factor Receptor in Neovascularization and Tumor Escape from Antiangiogenic Therapy. Clinical Genitourinary Cancer, 2012, 10, 77-83.	0.9	33
445	Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 90-95.	1.1	38
446	Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2012, 82, 200-212.	2.0	12
447	Fibroblast growth factors preserve blood–brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice. Neurobiology of Disease, 2012, 46, 204-214.	2.1	77
448	Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer, 2012, 12, 37.	1.1	28
449	Caveolinâ€1 orchestrates fibroblast growth factor 2 signaling control of angiogenesis in placental artery endothelial cell caveolae. Journal of Cellular Physiology, 2012, 227, 2480-2491.	2.0	41
450	A polypeptide from shark troponin I can inhibit angiogenesis and tumor growth. Molecular Biology Reports, 2012, 39, 1493-1501.	1.0	9
451	Dietary supplementation with curcumin enhances metastatic growth of Lewis lung carcinoma in mice. International Journal of Cancer, 2013, 132, 269-275.	2.3	9
452	Heparosanâ€Derived Heparan Sulfate/Heparinâ€Like Compounds: One Kind of Potential Therapeutic Agents. Medicinal Research Reviews, 2013, 33, 665-692.	5.0	43
453	Synergistic Promotion of Blood Vessel Regeneration by Astragaloside IV and Ferulic Acid from Electrospun Fibrous Mats. Molecular Pharmaceutics, 2013, 10, 2394-2403.	2.3	22
454	General Concepts of Blood Vessel Formation and Remodeling., 2013,, 1-23.		2
455	Sustained release of platelet-derived growth factor and vascular endothelial growth factor from silk/calcium phosphate/PLGA based nanocomposite scaffold. International Journal of Pharmaceutics, 2013, 454, 216-225.	2.6	70

#	Article	IF	CITATIONS
456	Localized delivery of growth factors for angiogenesis and bone formation in tissue engineering. International Immunopharmacology, 2013, 16, 214-223.	1.7	76
457	Targeting angiogenesis in renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2013, 14, 2221-2236.	0.9	37
458	Analysis of the fibroblast growth factor receptor (<scp>FGFR</scp>) signalling network with heparin as coreceptor: evidence for the expansion of the core <scp>FGFR</scp> signalling network. FEBS Journal, 2013, 280, 2260-2270.	2.2	24
459	<scp>GPNMB</scp> enhances bone regeneration by promoting angiogenesis and osteogenesis: Potential role for tissue engineering bone. Journal of Cellular Biochemistry, 2013, 114, 2729-2737.	1.2	53
460	Anti-metastatic and anti-angiogenic activities of sulfated polysaccharide of Sepiella maindroni ink. Carbohydrate Polymers, 2013, 91, 403-409.	5.1	46
461	A cytotoxic protein (BF-CT1) purified from Bungarus fasciatus venom acts through apoptosis, modulation of PI3K/AKT, MAPKinase pathway and cell cycle regulation. Toxicon, 2013, 74, 138-150.	0.8	9
462	Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. Cytotherapy, 2013, 15, 830-839.	0.3	58
463	Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4552-4556.	1.0	46
464	Naphthalimides exhibit inÂvitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs). European Journal of Medicinal Chemistry, 2013, 65, 477-486.	2.6	18
465	Treatment of metastatic cervical cancer: Future directions involving targeted agents. Critical Reviews in Oncology/Hematology, 2013, 85, 303-314.	2.0	71
466	Stimulatory effects of the ionic products from Ca–Mg–Si bioceramics on both osteogenesis and angiogenesis in vitro. Acta Biomaterialia, 2013, 9, 8004-8014.	4.1	192
467	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. Future Oncology, 2013, 9, 377-386.	1.1	18
468	Stimulation of proangiogenesis by calcium silicate bioactive ceramic. Acta Biomaterialia, 2013, 9, 5379-5389.	4.1	203
469	Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis, 2013, 16, 469-477.	3.7	38
470	Sprouty2 expression controls endothelial monolayer integrity and quiescence. Angiogenesis, 2013, 16, 455-468.	3.7	13
471	Associations of polymorphisms in the genes of <i>FGFR2</i> , <i>FGF</i> , <i>1</i> , and <i>RBFOX2</i> with breast cancer risk by estrogen/progesterone receptor status. Molecular Carcinogenesis, 2013, 52, 52-59.	1.3	10
472	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology, 2013, 31, 3517-3524.	0.8	675
473	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	3.2	62

#	Article	IF	CITATIONS
474	Gleditsioside B, a triterpene saponin isolated from the anomalous fruits of Gleditsia sinensis Lam., abrogates bFGF-induced endothelial cell migration through preventing the activation of MMP-2 and FAK via inhibiting ERK and PI3K/AKT signaling pathways. Vascular Pharmacology, 2013, 58, 118-126.	1.0	15
475	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 1257-1268.	3.2	117
476	Cooperative Heparin-Mediated Oligomerization of Fibroblast Growth Factor-1 (FGF1) Precedes Recruitment of FGFR2 to Ternary Complexes. Biophysical Journal, 2013, 104, 1720-1730.	0.2	42
477	Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2606-2619.	1.1	21
478	Increased levels of microRNA-424 are associated with the pathogenesis of fetal growth restriction. Placenta, 2013, 34, 624-627.	0.7	52
479	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	0.8	544
480	Cardiomyocyte FGF signaling is required for Cx43 phosphorylation and cardiac gap junction maintenance. Experimental Cell Research, 2013, 319, 2152-2165.	1.2	29
481	A novel plasmid and SonoVue formulation plus ultrasound sonication for effective gene delivery in nude mice. Life Sciences, 2013, 93, 536-542.	2.0	8
482	The effects of platelet gel–released supernatant on human fibroblasts. Wound Repair and Regeneration, 2013, 21, 300-308.	1.5	17
483	Emerging targeted agents in metastatic breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 191-210.	12.5	158
484	Topical Bacterial Lipopolysaccharide Application Affects Inflammatory Response and Promotes Wound Healing. Journal of Interferon and Cytokine Research, 2013, 33, 514-522.	0.5	29
485	Advances in Growth Factor Delivery for Therapeutic Angiogenesis. Journal of Vascular Research, 2013, 50, 35-51.	0.6	51
486	Reactive Oxygen Species in Physiologic and Pathologic Angiogenesis. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2013, , 71-92.	0.7	1
487	MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacological Research, 2013, 75, 15-27.	3.1	90
488	Bioactive silicate materials stimulate angiogenesis in fibroblast and endothelial cell co-culture system through paracrine effect. Acta Biomaterialia, 2013, 9, 6981-6991.	4.1	237
489	Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Frontiers of Medicine, 2013, 7, 25-30.	1.5	58
490	The role of angiogenic and wound-healing factors after spinal cord injury in mammals. Neuroscience Research, 2013, 76, 1-9.	1.0	36
491	Expression of pro―and antiâ€angiogenic factors during the formation of the periocular vasculature and development of the avian cornea. Developmental Dynamics, 2013, 242, 738-751.	0.8	12

#	Article	IF	CITATIONS
492	Angiogenic factors in bone local environment. Cytokine and Growth Factor Reviews, 2013, 24, 297-310.	3.2	208
493	The role of endosomal signaling triggered by metastatic growth factors in tumor progression. Cellular Signalling, 2013, 25, 1539-1545.	1.7	22
494	Ascorbic acid rescues cardiomyocyte development in Fgfr $1\hat{a}$ murine embryonic stem cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 140-147.	1.9	11
495	Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells. Molecular Cancer Therapeutics, 2013, 12, 2760-2771.	1.9	68
496	Promoted regeneration of mature blood vessels by electrospun fibers with loaded multiple pDNA-calcium phosphate nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 699-710.	2.0	31
497	Quantitative Proteome Analysis of Alveolar Type-II Cells Reveals a Connection of Integrin Receptor Subunits Beta 2/6 and WNT Signaling. Journal of Proteome Research, 2013, 12, 5598-5608.	1.8	10
498	The biochemistry of hematopoietic stem cell development. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2395-2403.	1.1	42
499	Fibroblast growth factor 2 induces the precocious development of endothelial cell networks in bovine luteinising follicular cells. Reproduction, Fertility and Development, 2013, 25, 372.	0.1	12
500	Sphingosine-1-phosphate induces VEGF-C expression through a MMP-2/FGF-1/FGFR-1-dependent pathway in endothelial cells in vitro. Acta Pharmacologica Sinica, 2013, 34, 360-366.	2.8	17
501	Role of sensory and motor intensity of electrical stimulation on fibroblastic growth factor-2 expression, inflammation, vascularization, and mechanical strength of full-thickness wounds. Journal of Rehabilitation Research and Development, 2013, 50, 489.	1.6	28
502	Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma. Seminars in Liver Disease, 2013, 33, S11-S19.	1.8	58
503	Angiogenesis and mast cell density as predictors of patient survival in squamous cell carcinoma of lung. Journal of Cancer Research and Therapeutics, 2013, 9, 701.	0.3	12
504	Inhibition of Metastatic Potential in Breast Carcinoma <i>In Vivo</i> and <i>In Vitro</i> through Targeting VEGFRs and FGFRs. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	9
505	Potential for Respiratory Epithelium Regeneration from Induced Pluripotent Stem Cells. Annals of Otology, Rhinology and Laryngology, 2013, 122, 25-32.	0.6	7
506	Fibroblast growth factor signaling promotes physiological bone remodeling and stem cell self-renewal. Current Opinion in Hematology, 2013, 20, 1.	1.2	24
507	Dynamics of Cytokine/Chemokine Responses in Intestinal CD4 ⁺ and CD8 ⁺ T Cells during Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2013, 87, 11916-11923.	1.5	32
508	Angiogenic Signaling and Structural Abnormalities in Tumors. , 2013, , 367-387.		0
509	Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). International Journal of Molecular Medicine, 2013, 32, 763-767.	1.8	140

#	Article	IF	CITATIONS
510	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 2171-2182.	0.9	16
511	Angiopoietins and Non–Vascular Endothelial Growth Factor Antiangiogenic Targets in Advanced Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2013, 19, 307-310.	1.0	5
512	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2013, 24, 220-225.	0.6	127
513	Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. British Journal of Pharmacology, 2013, 170, 712-729.	2.7	202
514	Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. Expert Review of Anticancer Therapy, 2013, 13, 1193-1206.	1.1	2
515	Long pentraxinâ€3 as an epithelial–stromal fibroblast growth factorâ€targeting inhibitor in prostate cancer. Journal of Pathology, 2013, 230, 228-238.	2.1	64
516	Genomic compartmentalization of gene families encoding core components of metazoan signaling systems. Genome, 2013, 56, 215-225.	0.9	2
517	Phase II angiogenesis stimulators. Expert Opinion on Investigational Drugs, 2013, 22, 1157-1166.	1.9	8
518	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1081-1088.	1.9	28
519	Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells. Journal of Biological Chemistry, 2013, 288, 7467-7480.	1.6	60
520	Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer. Molecular Medicine Reports, 2013, 7, 1381-1386.	1.1	6
521	Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using 1H HR-MAS spectroscopy and histopathology. Molecular Medicine Reports, 2013, 8, 1425-1431.	1.1	3
522	A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis. PLoS ONE, 2013, 8, e57927.	1.1	56
523	Crosstalk between Fibroblast Growth Factor (FGF) Receptor and Integrin through Direct Integrin Binding to FGF and Resulting Integrin-FGF-FGFR Ternary Complex Formation. Medical Sciences (Basel,) Tj ETQq1 1	Q <u>3</u> 8431	4 rgBT /Ove
524	Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 43.	1.8	7
525	BMP-2 promotes chondrogenesis of rat adipose-derived stem cells by using a lentiviral system. Genetics and Molecular Research, 2014, 13, 8620-8631.	0.3	6
526	Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis. Current Angiogenesis, 2014, 2, 76-95.	0.1	5
527	EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay. PLoS ONE, 2014, 9, e91849.	1.1	24

#	ARTICLE	IF	CITATIONS
528	FGF21 Promotes Endothelial Cell Angiogenesis through a Dynamin-2 and Rab5 Dependent Pathway. PLoS ONE, 2014, 9, e98130.	1.1	25
529	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence. Lung Cancer: Targets and Therapy, 2014, 5, 51.	1.3	2
530	Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets and Therapy, 2014, 7, 2237.	1.0	61
531	Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment. Current Signal Transduction Therapy, 2014, 9, 15-25.	0.3	4
532	MicroRNAs-Role in Lung Cancer. Disease Markers, 2014, 2014, 1-13.	0.6	62
533	The ins and outs of fibroblast growth factor receptor signalling. Clinical Science, 2014, 127, 217-231.	1.8	53
534	Fibroblast growth factor receptor 1 is a key inhibitor of $TGF\hat{l}^2$ signaling in the endothelium. Science Signaling, 2014, 7, ra90.	1.6	89
535	Glucose, Insulin, and Oxygen Interplay in Placental Hypervascularisation in Diabetes Mellitus. BioMed Research International, 2014, 2014, 1-12.	0.9	57
536	Ovarian Cancer-Related Hypophosphatemic Osteomalaciaâ€"A Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4403-4407.	1.8	31
537	New Role for Kruppel-like Factor 14 as a Transcriptional Activator Involved in the Generation of Signaling Lipids. Journal of Biological Chemistry, 2014, 289, 15798-15809.	1.6	49
538	The <scp>FGF</scp> â€1â€specific singleâ€chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis. Journal of Cellular and Molecular Medicine, 2014, 18, 2061-2070.	1.6	8
539	FGF signalling specifies haematopoietic stem cells through its regulation of somitic Notch signalling. Nature Communications, 2014, 5, 5583.	5.8	37
540	Glycogen synthase kinase 3 beta in somites plays a role during the angiogenesis of zebrafish embryos. FEBS Journal, 2014, 281, 4367-4383.	2.2	12
541	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research, 2014, 20, 3012-3022.	3.2	48
542	Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Review of Clinical Pharmacology, 2014, 7, 67-73.	1.3	9
543	Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. European Respiratory Review, 2014, 23, 79-91.	3.0	51
544	Fibromodulin Enhances Angiogenesis during Cutaneous Wound Healing. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e275.	0.3	39
545	Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13379-13384.	3.3	111

#	Article	IF	CITATIONS
546	FGF-2-Responsive and Spinal Cord-Resident Cells Improve Locomotor Function after Spinal Cord Injury. Journal of Neurotrauma, 2014, 31, 1584-1598.	1.7	27
547	Scaffold biomaterials for nano-pathophysiology. Advanced Drug Delivery Reviews, 2014, 74, 104-114.	6.6	12
548	Activation of the CXCL12/CXCR4 signaling axis may drive vascularization of the ovine placenta. Domestic Animal Endocrinology, 2014, 47, 11-21.	0.8	32
549	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World Journal of Urology, 2014, 32, 19-29.	1.2	10
550	Effects of combinations of BMP-2 with FGF-2 and/or VEGF on HUVECs angiogenesis in vitro and CAM angiogenesis in vivo. Cell and Tissue Research, 2014, 356, 109-121.	1.5	68
551	Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metabolism: Clinical and Experimental, 2014, 63, 860-873.	1.5	56
552	Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. Drugs, 2014, 74, 403-413.	4.9	84
553	Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 361-369.	1.2	15
554	The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clinical Pathology, 2014, 14, 5.	1.8	17
555	Electrosprayed Microparticles with Loaded pDNA-Calcium Phosphate Nanoparticles to Promote the Regeneration of Mature Blood Vessels. Pharmaceutical Research, 2014, 31, 874-886.	1.7	15
556	Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. Reproductive Biology, 2014, 14, 16-24.	0.9	10
557	Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment. Acta Biomaterialia, 2014, 10, 901-911.	4.1	51
558	Molecular mechanisms of angiogenesis effect of active sub-fraction from root of Rehmannia glutinosa by zebrafish sprout angiogenesis-guided fractionation. Journal of Ethnopharmacology, 2014, 151, 565-575.	2.0	20
559	Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway. Cancer Treatment Reviews, 2014, 40, 507-512.	3.4	22
560	Autoregulation of glypican-1 by intronic microRNA-149 fine-tunes the angiogenic response to fibroblast growth factor in human endothelial cells. Journal of Cell Science, 2014, 127, 1169-78.	1.2	61
561	Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis, 2014, 17, 109-118.	3.7	649
562	Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 687-695.	1.4	28
563	Nintedanib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 729-739.	0.9	11

#	Article	IF	CITATIONS
564	In vitro endothelial cell response to ionic dissolution products from boron-doped bioactive glass in the SiO ₂ â€"CaOâ€"P ₂ O ₅ â€"Na ₂ O system. Journal of Materials Chemistry B, 2014, 2, 7620-7630.	2.9	71
565	Radiogenomic Analysis of Breast Cancer: Luminal B Molecular Subtype Is Associated with Enhancement Dynamics at MR Imaging. Radiology, 2014, 273, 365-372.	3.6	206
566	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 305-315.	1.9	20
567	Bladder Acellular Matrix Conjugated with Basic Fibroblast Growth Factor for Bladder Regeneration. Tissue Engineering - Part A, 2014, 20, 2234-2242.	1.6	24
568	Spatioâ€temporally precise activation of engineered receptor tyrosine kinases by light. EMBO Journal, 2014, 33, 1713-1726.	3.5	226
569	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
570	Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. Experimental and Molecular Pathology, 2014, 97, 298-304.	0.9	60
571	Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways. Nutrition and Cancer, 2014, 66, 194-205.	0.9	72
572	Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies. Expert Review of Anticancer Therapy, 2014, 14, 621-639.	1.1	17
573	Silicate bioceramics enhanced vascularization and osteogenesis through stimulating interactions between endothelia cells and bone marrow stromal cells. Biomaterials, 2014, 35, 3803-3818.	5.7	216
574	Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Molecular Cancer, 2014, 13, 81.	7.9	42
575	Ginseng treatment reverses obesity and related disorders by inhibiting angiogenesis in female db/db mice. Journal of Ethnopharmacology, 2014, 155, 1342-1352.	2.0	36
576	Cytokine/Chemokine Responses in Activated CD4 ⁺ and CD8 ⁺ T Cells Isolated from Peripheral Blood, Bone Marrow, and Axillary Lymph Nodes during Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2014, 88, 9442-9457.	1.5	27
577	Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 161-179.	3.3	131
578	The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture. Cancer Letters, 2014, 346, 1-5.	3.2	52
579	The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Carcinogenesis, 2014, 35, 1144-1153.	1.3	45
580	Cyclic Adenosine Monophosphate-Response Element–Binding Protein Mediates the Proangiogenic or Proinflammatory Activity of Gremlin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 136-145.	1.1	45
581	Can we enhance fracture vascularity: What is the evidence?. Injury, 2014, 45, S49-S57.	0.7	44

#	Article	IF	CITATIONS
582	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 286-296.	5.1	239
583	Neonatal Human Dermal Fibroblasts Immobilized in RGD–Alginate Induce Angiogenesis. Cell Transplantation, 2014, 23, 945-957.	1.2	20
584	The efficacy of betulinic acid in triple-negative breast cancer. SAGE Open Medicine, 2014, 2, 205031211455197.	0.7	8
585	The emerging role of FGF receptor as a potential target in breast cancer. Breast Cancer Management, 2014, 3, 215-218.	0.2	1
586	Human FGF1 promoter is active in ependymal cells and dopaminergic neurons in the brains of F1Bâ€GFP transgenic mice. Developmental Neurobiology, 2015, 75, 232-248.	1.5	9
587	Basic fibroblast growth factor shows prognostic impact on survival in operable nonâ€small cell lung cancer patients. Thoracic Cancer, 2015, 6, 450-457.	0.8	6
590	Profile of nintedanib in the treatment of solid tumors: the evidence to date. OncoTargets and Therapy, 2015, 8, 3691.	1.0	58
591	Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 308-312.	0.5	8
592	Cancer-associated fibroblasts provide a suitable microenvironment for tumor development and progression in oral tongue squamous cancer. Journal of Translational Medicine, 2015, 13, 198.	1.8	49
593	Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling. Molecular Carcinogenesis, 2015, 54, 841-852.	1.3	13
594	Corneal Neovascularization: A Translational Perspective. Journal of Clinical & Experimental Ophthalmology, 2015, 06, .	0.1	0
595	In vitro and in vivo evaluation of carbonate apatite-collagen scaffolds with some cytokines for bone tissue engineering. Journal of Indian Prosthodontic Society, The, 2015, 15, 349.	0.3	6
596	Matrix Metalloproteinases-Modulating the Tumor Microenvironment. Journal of Carcinogenesis $\&$ Mutagenesis, 2015, 06, .	0.3	2
597	Association between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes. Journal of Korean Medical Science, 2015, 30, 586.	1.1	25
598	Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use. Molecules, 2015, 20, 6342-6388.	1.7	126
599	Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2015, 16, 53-70.	0.8	19
600	A Functional Role of Fibroblast Growth Factor Receptor 1 (FGFR1) in the Suppression of Influenza A Virus Replication. PLoS ONE, 2015, 10, e0124651.	1.1	13
602	Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2015, 15, 71-85.	0.5	22

#	Article	IF	Citations
603	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	0.8	10
604	A Direct Role for ATP1A1 in Unconventional Secretion of Fibroblast Growth Factor 2. Journal of Biological Chemistry, 2015, 290, 3654-3665.	1.6	51
605	Decreasing matrix modulus of PEG hydrogels induces a vascular phenotype in human cord blood stem cells. Biomaterials, 2015, 62, 24-34.	5.7	20
606	miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagnostic Pathology, 2015, 10, 24.	0.9	58
607	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 1367-1369.	1.1	23
608	CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo. International Journal of Oncology, 2015, 46, 2181-2193.	1.4	20
609	Gingival Wound Healing. Journal of Dental Research, 2015, 94, 395-402.	2.5	48
610	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opinion on Therapeutic Targets, 2015, 19, 675-685.	1.5	28
611	Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 5-12.	1.2	25
612	Skin Wound Healing. , 2015, , 631-651.		0
613	Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell Carcinoma. Oncology, 2015, 88, 321-331.	0.9	13
614	HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. Experimental Cell Research, 2015, 331, 46-57.	1.2	36
615	Tumor Angiogenesis. , 2015, , 257-268.e2.		5
616	Formation of Disulfide Bridges Drives Oligomerization, Membrane Pore Formation, and Translocation of Fibroblast Growth Factor 2 to Cell Surfaces. Journal of Biological Chemistry, 2015, 290, 8925-8937.	1.6	51
617	Fibroblast Growth Factor Signaling Pathway in Endothelial Cells Is Activated by BMPER to Promote Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 358-367.	1.1	41
618	Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1116-1122.	1.4	18
619	Genome-wide expression analysis of wounded skin reveals novel genes involved in angiogenesis. Angiogenesis, 2015, 18, 361-371.	3.7	10
620	Endothelial MMP14 is required for endothelial dependent growth support of human airway basal cells. Journal of Cell Science, 2015, 128, 2983-8.	1.2	13

#	Article	IF	Citations
621	Preparation and preliminary (i>in vitro \langle i>evaluation of a bFGF-releasing heparin-conjugated poly ($\hat{l}\mu$ -caprolactone) membrane for guided bone regeneration. Journal of Biomaterials Science, Polymer Edition, 2015, 26, 600-616.	1.9	12
622	Membraneâ€Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factorâ€2 Binding to the Cell Surface and Intracellular Signaling. Journal of Cellular Physiology, 2015, 230, 366-377.	2.0	13
623	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist, 2015, 20, 660-673.	1.9	436
624	Optimization of treatment with recombinant FGF-2 for proliferation and differentiation of human dental stem cells, mesenchymal stem cells, and osteoblasts. Biochemistry and Cell Biology, 2015, 93, 298-305.	0.9	23
625	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	1.5	72
626	Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Review of Anticancer Therapy, 2015, 15, 579-594.	1.1	17
627	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer and Metastasis Reviews, 2015, 34, 19-40.	2.7	76
628	Angiogenesis in salivary gland tumors: from clinical significance to treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 807-819.	1.5	9
629	The role of FGF-2/HGF and fibronectin matrix on pleomorphic adenoma myoepithelial cell morphology and immunophenotype: anin vitrostudy. Growth Factors, 2015, 33, 50-56.	0.5	1
630	Effect of silver nanoparticles and hydroxyproline, administered <i>in ovo </i> , on the development of blood vessels and cartilage collagen structure in chicken embryos. Archives of Animal Nutrition, 2015, 69, 57-68.	0.9	25
631	Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle, 2015, 14, 2121-2128.	1.3	39
632	Fibroblast Growth Factor Signaling in the Vasculature. Current Atherosclerosis Reports, 2015, 17, 509.	2.0	69
633	The Startling Properties of Fibroblast Growth Factor 2: How to Exit Mammalian Cells without a Signal Peptide at Hand. Journal of Biological Chemistry, 2015, 290, 27015-27020.	1.6	47
634	An integrated approach to quantitative modelling in angiogenesis research. Journal of the Royal Society Interface, 2015, 12, 20150546.	1.5	23
635	Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. Critical Reviews in Oncology/Hematology, 2015, 96, 195-205.	2.0	7
636	Decreased anti-regenerative effects after spinal cord injury in spry4â^'/â^' mice. Neuroscience, 2015, 287, 104-112.	1.1	8
637	Dendritic Polymers in Targeted Drug Delivery. Advances in Delivery Science and Technology, 2015, , 543-569.	0.4	3
638	Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis. Arthritis and Rheumatology, 2015, 67, 498-507.	2.9	54

#	Article	IF	CITATIONS
639	The Antiparasitic Drug, Potassium Antimony Tartrate, Inhibits Tumor Angiogenesis and Tumor Growth in Nonsmall-Cell Lung Cancer. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 129-138.	1.3	22
640	Asthma is not only an airway disease, but also a vascular disease. , 2015, 148, 17-33.		52
641	Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine and Growth Factor Reviews, 2015, 26, 293-310.	3.2	26
642	Enhanced effect of \hat{l}^2 -tricalcium phosphate phase on neovascularization of porous calcium phosphate ceramics: In vitro and in vivo evidence. Acta Biomaterialia, 2015, 11, 435-448.	4.1	106
643	Controlled protein delivery in the generation of microvascular networks. Drug Delivery and Translational Research, 2015, 5, 75-88.	3.0	8
644	Tumor Vasculature Is Regulated by FGF/FGFR Signalingâ€Mediated Angiogenesis and Bone Marrowâ€Derived Cell Recruitment: This Mechanism Is Inhibited by SSR128129E, the First Allosteric Antagonist of FGFRs. Journal of Cellular Physiology, 2015, 230, 43-51.	2.0	23
645	Dual Inhibitory Pathways of Metallofullerenol Gd@C82(OH)22 on Matrix Metalloproteinase-2: Molecular insight into drug-like nanomedicine. Scientific Reports, 2014, 4, 4775.	1.6	25
646	The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. Cytotechnology, 2015, 67, 969-975.	0.7	26
647	Effects of microplasma irradiation on human gingival fibroblasts. Odontology / the Society of the Nippon Dental University, 2015, 103, 194-202.	0.9	4
648	Unconventional Secretion of Fibroblast Growth Factor 2â€"A Novel Type of Protein Translocation across Membranes?. Journal of Molecular Biology, 2015, 427, 1202-1210.	2.0	56
649	Growth factor conjugation: Strategies and applications. Journal of Biomedical Materials Research - Part A, 2015, 103, 819-838.	2.1	58
650	Angiogenesis in Peripheral Artery Disease: Focus on Growth Factor Therapy. , 2016, , 1-16.		0
651	Hepatocellular carcinoma: Where are we?. World Journal of Experimental Medicine, 2016, 6, 21.	0.9	104
652	Fibroblast Growth Factors and their Emerging Cancer-Related Aspects. Journal of Cancer Science & Therapy, 2016, 08, .	1.7	4
653	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. Journal of Gastrointestinal Oncology, 2016, 7, 789-796.	0.6	26
654	Identifying significant pathways of hepatitis B virus-related hepatocellular carcinoma based on crosstalk and network pathways. Genetics and Molecular Research, 2016, 15 , .	0.3	2
655	Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 1489.	1.8	59
656	Integrating Transcriptomic and Proteomic Data Using Predictive Regulatory Network Models of Host Response to Pathogens. PLoS Computational Biology, 2016, 12, e1005013.	1.5	24

#	Article	IF	CITATIONS
657	Molecular Survey of Cell Source Usage during Subtotal Hepatectomy-Induced Liver Regeneration in Rats. PLoS ONE, 2016, 11, e0162613.	1.1	12
658	Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy, 2016, 10, 1857.	2.0	164
659	The progress of angiogenic factors in the development of leukemias. Intractable and Rare Diseases Research, 2016, 5, 6-16.	0.3	13
660	Tumor cell intravasation. American Journal of Physiology - Cell Physiology, 2016, 311, C1-C14.	2.1	225
661	Inhibition of blood vessel formation in tumors by <scp>IL</scp> â€18â€polarized M1 macrophages. Genes To Cells, 2016, 21, 287-295.	0.5	13
662	Co-delivery of VEGF and bFGF via a PLGA nanoparticle-modified BAM for effective contracture inhibition of regenerated bladder tissue in rabbits. Scientific Reports, 2016, 6, 20784.	1.6	45
663	How interacting pathways are regulated by miRNAs in breast cancer subtypes. BMC Bioinformatics, 2016, 17, 348.	1.2	20
664	Unconventional Protein Secretion: Fibroblast Growth Factor 2 and Interleukin- $\hat{l^2}$ as Examples. , 2016, , 520-527.		1
665	The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 62-67.	0.5	4
666	Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population. Scientific Reports, 2016, 6, 33604.	1.6	4
667	Substituted quinazolinones as kinase inhibitors endowed with anti-fibrotic properties. European Journal of Medicinal Chemistry, 2016, 115, 416-425.	2.6	12
668	Spheroid-Based In Vitro Angiogenesis Model. Methods in Molecular Biology, 2016, 1430, 167-177.	0.4	30
669	Homozygous Mutation of the <i>FGFR1</i> Gene Associated with Congenital Heart Disease and 46,XY Disorder of Sex Development. Sexual Development, 2016, 10, 16-22.	1.1	11
670	A photo-polymerized poly(Nε-acryloyl l-lysine) hydrogel for 3D culture of MCF-7 breast cancer cells. Journal of Materials Chemistry B, 2016, 4, 3339-3350.	2.9	4
671	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	2.9	29
672	A Naturally Derived, Growth Factor-Binding Polysaccharide for Therapeutic Angiogenesis. ACS Macro Letters, 2016, 5, 617-621.	2.3	32
673	Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects. Cancer Letters, 2016, 377, 164-173.	3.2	60
674	Angiogenesis Protocols. Methods in Molecular Biology, 2016, , .	0.4	4

#	Article	IF	Citations
675	A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2). Biomacromolecules, 2016, 17, 3386-3395.	2.6	36
676	Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. BioDrugs, 2016, 30, 421-439.	2.2	9
678	Insights into the anti-angiogenic properties of phosphaplatins. Journal of Inorganic Biochemistry, 2016, 164, 5-16.	1.5	10
679	FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage nonâ€small cell lung cancer. Journal of Pathology: Clinical Research, 2016, 2, 223-233.	1.3	38
680	Small Molecule Inhibitors Targeting Tec Kinase Block Unconventional Secretion of Fibroblast Growth Factor 2. Journal of Biological Chemistry, 2016, 291, 17787-17803.	1.6	32
681	Construction of a disulfideâ€stabilized diabody against fibroblast growth factorâ€2 and the inhibition activity in targeting breast cancer. Cancer Science, 2016, 107, 1141-1150.	1.7	19
682	Expression of Cytokine Genes and Growth Factors in Rat Lungs and Kidneys after Subtotal Hepatectomy. Bulletin of Experimental Biology and Medicine, 2016, 161, 395-399.	0.3	4
683	An electrophysiological study on the effects of BDNF and FGF2 on voltage dependent Ca 2+ currents in developing human striatal primordium. Molecular and Cellular Neurosciences, 2016, 75, 50-62.	1.0	9
684	Differential proteomic analysis of respiratory samples from patients suffering from influenza. VirusDisease, 2016, 27, 226-233.	1.0	3
685	Nanoparticles combined with growth factors: recent progress and applications. RSC Advances, 2016, 6, 90856-90872.	1.7	19
686	Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews Molecular Cell Biology, 2016, 17, 611-625.	16.1	1,034
687	Homology modeling and virtual screening studies of FGF-7 protein—a structure-based approach to design new molecules against tumor angiogenesis. Journal of Chemical Biology, 2016, 9, 69-78.	2.2	13
688	Anti-angiogenic Therapy for Retinal Disease. Handbook of Experimental Pharmacology, 2016, 242, 271-307.	0.9	38
689	Endothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult. Scientific Reports, 2016, 5, 17705.	1.6	20
690	Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Scientific Reports, 2016, 6, 23432.	1.6	20
691	Angiogenic microspheres promote neural regeneration and motor function recovery after spinal cord injury in rats. Scientific Reports, 2016, 6, 33428.	1.6	64
692	Design principles for the rapeutic angiogenic materials. Nature Reviews Materials, 2016, 1 , .	23.3	125
693	Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. Molecular Therapy, 2016, 24, 1974-1986.	3.7	37

#	Article	IF	CITATIONS
694	Hepatocellular Carcinoma $\hat{a} \in$ "Liver Transplantation, Hepatic Resection, and Regional Treatment Options. , 2016, , 391-421.		0
695	N-Cadherin and Fibroblast Growth Factor Receptors crosstalk in the control of developmental and cancer cell migrations. European Journal of Cell Biology, 2016, 95, 415-426.	1.6	41
696	Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm. Clinical Lung Cancer, 2016, 17, 493-506.	1.1	16
697	Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas. Tumor Biology, 2016, 37, 4889-4900.	0.8	1
698	Regulation of fibroblast growth factor $15/19$ and 21 on metabolism: in the fed or fasted state. Journal of Translational Medicine, 2016, 14, 63.	1.8	25
699	MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs. Tumor Biology, 2016, 37, 9527-9534.	0.8	40
700	Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. Cancer Chemotherapy and Pharmacology, 2016, 77, 905-926.	1.1	15
701	FGFR Signaling as a Target for Lung Cancer Therapy. Journal of Thoracic Oncology, 2016, 11, 9-20.	0.5	82
702	Anti-angiogenesis in Personalized Therapy of Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 91-126.	0.8	17
704	In vivo and in vitro studies of borate based glass micro-fibers for dermal repairing. Materials Science and Engineering C, 2016, 60, 437-445.	3.8	7 3
705	Context-Dependent Development of Lymphoid Stroma from Adult CD34+ Adventitial Progenitors. Cell Reports, 2016, 14, 2375-2388.	2.9	70
706	Blocking the FGF/FGFR system as a â¿¿two-compartmentâ¿¿ antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	3.1	69
707	Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology, 2016, 69, 472-483.	1.0	55
708	Cancer and Angiogenesis. , 2016, , 39-54.		0
709	Staphylococcus aureus induces TGF- \hat{l}^2 1 and bFGF expression through the activation of AP-1 and NF- \hat{l}^2 B transcription factors in bovine mammary gland fibroblasts. Microbial Pathogenesis, 2016, 95, 7-14.	1.3	13
710	bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice. Journal of Assisted Reproduction and Genetics, 2016, 33, 281-289.	1.2	45
711	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. Expert Opinion on Investigational Drugs, 2016, 25, 31-49.	1.9	35
712	Microscale Technologies for Engineering Complex Tissue Structures. , 2016, , 3-25.		6

#	ARTICLE	IF	CITATIONS
713	Preparation and characterization of pro-angiogenic gel derived from small intestinal submucosa. Acta Biomaterialia, 2016, 29, 135-148.	4.1	73
714	VEGF-Induced Expression of miR-17–92 Cluster in Endothelial Cells Is Mediated by ERK/ELK1 Activation and Regulates Angiogenesis. Circulation Research, 2016, 118, 38-47.	2.0	141
715	Anticoagulant and FGF/FGFR signal activating activities of the heparinoid propylene glycol alginate sodium sulfate and its oligosaccharides. Carbohydrate Polymers, 2016, 136, 641-648.	5.1	23
716	Therapeutic uses of FGFs. Seminars in Cell and Developmental Biology, 2016, 53, 144-154.	2.3	36
717	Strategies to direct vascularisation using mesoporous bioactive glass-based biomaterials for bone regeneration. International Materials Reviews, 2017, 62, 392-414.	9.4	44
718	Fibroblast Growth Factor 7 Regulates Proliferation and Decidualization of Human Endometrial Stromal Cells via ERK and JNK Pathway in an Autocrine Manner. Reproductive Sciences, 2017, 24, 1607-1619.	1.1	19
719	Elaboration and evaluation of alginate foam scaffolds for soft tissue engineering. International Journal of Pharmaceutics, 2017, 524, 433-442.	2.6	30
720	FGF Ligand Traps for the Therapy of FGF-Dependent Tumors. , 2017, , 237-269.		0
721	High molecular weight FGF2 isoforms demonstrate canonical receptor-mediated activity and support human embryonic stem cell self-renewal. Stem Cell Research, 2017, 21, 106-116.	0.3	19
722	Sprouting strategies and dead ends in anti-angiogenic targeting of NETs. Journal of Molecular Endocrinology, 2017, 59, R77-R91.	1.1	9
723	Molecular Genetics of Endometrial Carcinoma. Advances in Experimental Medicine and Biology, 2017, , .	0.8	6
724	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
725	Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation, 2017, 101, 778-785.	0.5	23
726	Experimental intermittent ischemia augments exercise-induced inflammatory cytokine production. Journal of Applied Physiology, 2017, 123, 434-441.	1.2	9
727	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach., 2017, 179, 171-187.		152
728	FGF in Cardiovascular Disease. , 2017, , 129-151.		0
729	Therapeutic Potential of Allosteric Modulation of FGF Receptors. , 2017, , 169-185.		0
730	Growth Factors in the Eye. , 2017, , 211-236.		0

#	Article	IF	CITATIONS
731	Acute lung injury complicating acute kidney injury: A model of endogenous \hat{l} ±Klotho deficiency and distant organ dysfunction. Bone, 2017, 100, 100-109.	1.4	24
732	Role of caveolin-1/vascular endothelial growth factor pathway in basic fibroblast growth factor-induced angiogenesis and neurogenesis after treadmill training following focal cerebral ischemia in rats. Brain Research, 2017, 1663, 9-19.	1.1	48
733	Relationships Between MRI Breast Imaging-Reporting and Data System (BI-RADS) Lexicon Descriptors and Breast Cancer Molecular Subtypes: Internal Enhancement is Associated with Luminal B Subtype. Breast Journal, 2017, 23, 579-582.	0.4	35
734	Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. Expert Opinion on Investigational Drugs, 2017, 26, 1295-1305.	1.9	5
735	Synergetic stimulation of nanostructure and chemistry cues on behaviors of fibroblasts and endothelial cells. Colloids and Surfaces B: Biointerfaces, 2017, 160, 500-509.	2.5	8
736	Therapeutic Angiogenesis for PeripheralÂArtery Disease. JACC Basic To Translational Science, 2017, 2, 503-512.	1.9	70
737	A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration. Cardiovascular Research, 2017, 113, 1585-1602.	1.8	23
738	The expression and function of miR-424 in infantile skin hemangioma and its mechanism. Scientific Reports, 2017, 7, 11846.	1.6	26
739	FGF-2-mediated FGFR1 signaling in human microvascular endothelial cells is activated by vaccarin to promote angiogenesis. Biomedicine and Pharmacotherapy, 2017, 95, 144-152.	2.5	41
740	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.	2.0	13
741	Therapeutic Angiogenesis, Cell Therapy and Peripheral Vascular Disease., 2017,, 327-342.		0
742	An emerging case for membrane pore formation as a common mechanism for the unconventional secretion of FGF2 and IL- $1\hat{l}^2$. Journal of Cell Science, 2017, 130, 3197-3202.	1.2	39
743	Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma. Molecular Medicine Reports, 2017, 16, 1643-1652.	1.1	4
744	Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene, 2017, 36, 6531-6541.	2.6	33
745	The molecular mechanism underlying unconventional secretion of Fibroblast Growth Factor 2 from tumour cells. Biology of the Cell, 2017, 109, 375-380.	0.7	9
746	Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women. Oncology Letters, 2017, 14, 1561-1567.	0.8	14
747	Antitumoral effects of Î ³ CdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Scientific Reports, 2017, 7, 7077.	1.6	17
748	Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLCâ€'05 lung cancer cells. Molecular Medicine Reports, 2017, 17, 911-917.	1.1	10

#	Article	IF	CITATIONS
749	Periodontal soft tissue reconstruction. , 2017, , 257-278.		2
751	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 169-175.	0.4	8
752	Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy. World Journal of Surgical Oncology, 2017, 15, 66.	0.8	13
753	Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 2017, 43, 581-593.	0.5	45
754	Luteal Angiogenesis., 2017, , 1-21.		2
755	Gas-Phase Analysis of the Complex of Fibroblast GrowthFactor 1 with Heparan Sulfate: A Traveling Wave Ion Mobility Spectrometry (TWIMS) and Molecular Modeling Study. Journal of the American Society for Mass Spectrometry, 2017, 28, 96-109.	1.2	18
756	Fineâ€ŧuning vascular fate during endothelial–mesenchymal transition. Journal of Pathology, 2017, 241, 25-35.	2.1	62
757	Disrupting Tumor Angiogenesis and "the Hunger Games―for Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 171-195.	0.8	11
758	Molecular Regulation of Sprouting Angiogenesis. , 2017, 8, 153-235.		47
759	Bone morphogenetic protein 4 regulates microRNAs miR-494 and miR-126–5p in control of endothelial cell function in angiogenesis. Thrombosis and Haemostasis, 2017, 117, 734-749.	1.8	40
760	In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3. International Journal of Nanomedicine, 2017, Volume 12, 5345-5357.	3.3	4
761	The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche. International Journal of Molecular Sciences, 2017, 18, 2342.	1.8	39
762	The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. International Journal of Molecular Sciences, 2017, 18, 2452.	1.8	45
763	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. International Journal of Molecular Sciences, 2017, 18, 418.	1.8	47
764	Screening candidate microRNAs (miRNAs) in different lambskin hair follicles in Hu sheep. PLoS ONE, 2017, 12, e0176532.	1.1	40
765	Locoregional and systemic therapy for hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 215-228.	0.6	64
766	The effect of hydrazine derivatives of 3-formylchromones on angiogenic basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanoma cell line WM-115. Acta Biochimica Polonica, 2017, 64, 585-590.	0.3	6
768	Lenvatinib for the treatment of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 507-512.	1.9	14

#	Article	IF	CITATIONS
769	Expression and clinical significance of serum MMPâ€'7 and PTEN levels in patients with acute myeloid leukemia. Oncology Letters, 2018, 15, 3447-3452.	0.8	12
770	Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. Journal of Cellular Physiology, 2018, 233, 2949-2965.	2.0	98
771	Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis. Cellular Immunology, 2018, 323, 19-32.	1.4	77
772	Bioglass enhanced wound healing ability of urineâ€derived stem cells through promoting paracrine effects between stem cells and recipient cells. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, e1609-e1622.	1.3	23
773	Angiogenic Growth Factors for Coronary Artery Disease: Current Status and Prospects. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 130-141.	1.0	9
774	Aptamers as therapeutic middle molecules. Biochimie, 2018, 145, 22-33.	1.3	17
775	N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. Angiogenesis, 2018, 21, 47-59.	3.7	27
776	Growth-Factor-Releasing Polyelectrolyte Multilayer Films to Control the Cell Culture Environment. Langmuir, 2018, 34, 1178-1189.	1.6	14
777	Endothelialâ€ŧoâ€mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry. Developmental Dynamics, 2018, 247, 492-508.	0.8	120
778	Fibroblast growth factor 9 subfamily and the heart. Applied Microbiology and Biotechnology, 2018, 102, 605-613.	1.7	16
779	Comparative study of the effect of different fucoidans from Sargassum maclurei and Saccharina japonica on FGFs/FGFR signaling activation in BaF3 cells. International Journal of Biological Macromolecules, 2018, 107, 2429-2435.	3.6	3
780	A gene-activating skin substitute comprising PLLA/POSS nanofibers and plasmid DNA encoding ANG and bFGF promotes <i>in vivo</i> revascularization and epidermalization. Journal of Materials Chemistry B, 2018, 6, 6977-6992.	2.9	14
781	Innovative Methodology of On-Line Point Cloud Data Compression for Free-Form Surface Scanning Measurement. Applied Sciences (Switzerland), 2018, 8, 2556.	1.3	2
782	Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. Frontiers in Oncology, 2018, 8, 472.	1.3	24
783	FGF10 Signaling in Heart Development, Homeostasis, Disease and Repair. Frontiers in Genetics, 2018, 9, 599.	1.1	26
784	Platelet-Rich Plasma Prevents In Vitro Transforming Growth Factor-β1-Induced Fibroblast to Myofibroblast Transition: Involvement of Vascular Endothelial Growth Factor (VEGF)-A/VEGF Receptor-1-Mediated Signaling â€. Cells, 2018, 7, 142.	1.8	31
785	A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. Scientific Reports, 2018, 8, 14091.	1.6	19
786	Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. Frontiers in Immunology, 2018, 9, 2327.	2.2	60

#	Article	IF	CITATIONS
787	Application of PLGA/FGF-2 coaxial microfibers in spinal cord tissue engineering: an <i>in vitro</i> and <i>in vivo</i> investigation. Regenerative Medicine, 2018, 13, 785-801.	0.8	25
788	Targeting Difficult Protein-Protein Interactions with Plain and General Computational Approaches. Molecules, 2018, 23, 2256.	1.7	6
789	Bradykinin B2 Receptor Contributes to Inflammatory Responses in Human Endothelial Cells by the Transactivation of the Fibroblast Growth Factor Receptor FGFR-1. International Journal of Molecular Sciences, 2018, 19, 2638.	1.8	16
791	Methods to Investigate the Roles of Progranulin in Angiogenesis Using In Vitro Strategies and Transgenic Mouse Models. Methods in Molecular Biology, 2018, 1806, 329-360.	0.4	2
792	Overexpression of \$100A13 protein is associated with tumor angiogenesis and poor survival in patients with earlyâ€stage nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1136-1144.	0.8	18
793	The Blood Vessel Wall. , 2018, , 1843-1856.e6.		1
794	Dual release of growth factor from nanocomposite fibrous scaffold promotes vascularisation and bone regeneration in rat critical sized calvarial defect. Acta Biomaterialia, 2018, 78, 36-47.	4.1	85
795	A pilot study to profile salivary angiogenic factors to detect head and neck cancers. BMC Cancer, 2018, 18, 734.	1.1	9
796	FGF Mutants. , 2018, , 145-215.		0
797	Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. International Journal of Molecular Sciences, 2018, 19, 43.	1.8	72
798	Effect of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogels on frozenâ€thawed human ovarian tissue in a xenograft model. Journal of Obstetrics and Gynaecology Research, 2018, 44, 1947-1955.	0.6	18
799	Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Frontiers in Bioscience - Landmark, 2018, 23, 626-639.	3.0	39
800	Antiangiogenic Therapies in Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 45-58.	0.9	38
801	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	3.7	169
802	Genetic Modifiers of the Breast Tumor Microenvironment. Trends in Cancer, 2018, 4, 429-444.	3.8	29
803	Fine-tuning of fgf8a expression through alternative polyadenylation has a selective impact on Fgf-associated developmental processes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 783-793.	0.9	0
804	Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity. International Journal of Molecular Sciences, 2018, 19, 2470.	1.8	7
805	Hydrogel vehicles for sequential delivery of protein drugs to promote vascular regeneration. Advanced Drug Delivery Reviews, 2019, 149-150, 95-106.	6.6	52

#	Article	IF	CITATIONS
806	Inflammation and angiogenesis in the corpus luteum. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1967-1974.	0.6	11
807	Bioinformatics prediction and analysis of hub genes and pathways of three types of gynecological cancer. Oncology Letters, 2019, 18, 617-628.	0.8	16
808	Fibroblast growth factor receptor inhibitors: patent review (2015–2019). Expert Opinion on Therapeutic Patents, 2019, 29, 965-977.	2.4	11
809	mRNA and miRNA Transcriptome Profiling of Granulosa and Theca Layers From Geese Ovarian Follicles Reveals the Crucial Pathways and Interaction Networks for Regulation of Follicle Selection. Frontiers in Genetics, 2019, 10, 988.	1.1	38
810	Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model. Biomolecules, 2019, 9, 644.	1.8	3
811	Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease. Molecular Therapy - Nucleic Acids, 2019, 17, 819-828.	2.3	37
812	Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules, 2019, 24, 3316.	1.7	26
813	Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 2019, 8, 1102.	1.8	150
814	Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge. Cytokine and Growth Factor Reviews, 2019, 46, 54-65.	3.2	4
815	Thyroid dysfunction from inhibitor of fibroblast growth factor receptor. Experimental Hematology and Oncology, 2019, 8, 6.	2.0	3
816	Improving the protective effects of aFGF for peripheral nerve injury repair using sulfated chitooligosaccharides. Asian Journal of Pharmaceutical Sciences, 2019, 14, 511-520.	4.3	14
817	Neurovascular interactions in skin wound healing. Neurochemistry International, 2019, 125, 144-150.	1.9	30
818	Non-Thermal Plasma Accelerates Astrocyte Regrowth and Neurite Regeneration Following Physical Trauma In Vitro. Applied Sciences (Switzerland), 2019, 9, 3747.	1.3	14
819	Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells. Cell Cycle, 2019, 18, 3562-3580.	1.3	24
820	Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers. Molecules, 2019, 24, 4630.	1.7	8
821	Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Frontiers in Oncology, 2019, 9, 1370.	1.3	570
822	Fine epitope mapping of a human disulphide-stabilized diabody against fibroblast growth factor-2. Journal of Biochemistry, 2019, 165, 487-495.	0.9	3
823	Molecular interactions in juvenile nasopharyngeal angiofibroma: preliminary signature and relevant review. European Archives of Oto-Rhino-Laryngology, 2019, 276, 93-100.	0.8	7

#	Article	IF	CITATIONS
824	C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica, 2019, 40, 823-832.	2.8	18
825	Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2019, 83, 551-559.	1.1	6
826	Therapeutic angiogenesis: From conventional approaches to recent nanotechnology-based interventions. Materials Science and Engineering C, 2019, 97, 994-1008.	3.8	34
827	Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling. Journal of Agricultural and Food Chemistry, 2019, 67, 1127-1137.	2.4	33
828	Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases. International Journal of Peptide Research and Therapeutics, 2020, 26, 107-119.	0.9	8
829	Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 2020, 77, 1745-1770.	2.4	927
830	Toxicity of cooking oil fume derived particulate matter: Vitamin D3 protects tubule formation activation in human umbilical vein endothelial cells. Ecotoxicology and Environmental Safety, 2020, 188, 109905.	2.9	21
831	Mesoglycan induces the secretion of microvesicles by keratinocytes able to activate human fibroblasts and endothelial cells: A novel mechanism in skin wound healing. European Journal of Pharmacology, 2020, 869, 172894.	1.7	27
832	Fibroblast growth factor-2 signaling modulates matrix reorganization and cell cycle turnover rate in the regenerating tail of Hemidactylus flaviviridis. Acta Histochemica, 2020, 122, 151464.	0.9	4
833	Cancer Stem Cells: New Horizons in Cancer Therapies. , 2020, , .		1
834	Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer. Journal of Receptor and Signal Transduction Research, 2020, 41, 1-7.	1.3	2
835	Angiogenic effects of low molecular weight organic acids present in fulvic acids of different sources. Natural Product Research, 2021, 35, 6153-6157.	1.0	3
836	Chronic elevation of plasma vascular endothelial growth factor-A (VEGF-A) is associated with a history of blast exposure. Journal of the Neurological Sciences, 2020, 417, 117049.	0.3	9
837	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. Cancers, 2020, 12, 3299.	1.7	14
838	FGF2 and IL-1β â \in " explorers of unconventional secretory pathways at a glance. Journal of Cell Science, 2020, 133, .	1.2	30
839	A role for fibroblast growth factor receptor 1 in the pathogenesis of Neisseria meningitidis. Microbial Pathogenesis, 2020, 149, 104534.	1.3	5
840	FGF/FGFR signaling in health and disease. Signal Transduction and Targeted Therapy, 2020, 5, 181.	7.1	339
841	Generation of a Heparan Sulfate Mutant Cell Library and Its Application to Determine the Structure-Function Relationship of Heparan Sulfate in Facilitating FGF2-FGFR1 Signaling. ACS Symposium Series, 2020, , 39-46.	0.5	O

#	Article	IF	Citations
842	Collagen hydrogels loaded with fibroblast growth factor-2 as a bridge to repair brain vessels in organotypic brain slices. Experimental Brain Research, 2020, 238, 2521-2529.	0.7	17
843	Growth Factors and Small-molecule Compounds in Derivation of Endothelial Lineages from Dental Stem Cells. Journal of Endodontics, 2020, 46, S63-S70.	1.4	1
844	Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. International Journal of Molecular Sciences, 2020, 21, 5840.	1.8	143
845	Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy. Technology in Cancer Research and Treatment, 2020, 19, 153303382098011.	0.8	20
846	Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in Scirrhous Type Gastric Cancer. Frontiers in Oncology, 2020, 10, 568557.	1.3	26
847	Fabrication of Artificial Nanobasement Membranes for Cell Compartmentalization in 3D Tissues. Small, 2020, 16, e1907434.	5.2	16
848	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers, 2020, 12, 1330.	1.7	7
849	Differentiation between Luminal A and B Molecular Subtypes of Breast Cancer Using Pharmacokinetic Quantitative Parameters with Histogram and Texture Features on Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Academic Radiology, 2020, 27, e35-e44.	1.3	17
850	Performance of preoperative breast MRI based on breast cancer molecular subtype. Clinical Imaging, 2020, 67, 130-135.	0.8	4
851	ColXV Aggravates Adipocyte Apoptosis by Facilitating Abnormal Extracellular Matrix Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 959.	1.8	3
852	Initiation of Conceptus Elongation Coincides with an Endometrium Basic Fibroblast Growth Factor (FGF2) Protein Increase in Heifers. International Journal of Molecular Sciences, 2020, 21, 1584.	1.8	5
853	Computer simulations of protein–membrane systems. Progress in Molecular Biology and Translational Science, 2020, 170, 273-403.	0.9	31
854	Temperature-Responsive Multifunctional Protein Hydrogels with Elastin-like Polypeptides for 3-D Angiogenesis. Biomacromolecules, 2020, 21, 1126-1135.	2.6	33
855	FGFR1 is associated with câ€MYC and proangiogenic molecules in metastatic renal cell carcinoma under antiâ€angiogenic therapy. Histopathology, 2020, 76, 838-851.	1.6	5
856	Multifunctional coatings combining bioactive peptides and affinity-based cytokine delivery for enhanced integration of degradable vascular grafts. Biomaterials Science, 2020, 8, 1734-1747.	2.6	18
857	The Role of Glypican-1 in the Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1245, 163-176.	0.8	31
858	Modified bacterial outer membrane vesicles induce autoantibodies for tumor therapy. Acta Biomaterialia, 2020, 108, 300-312.	4.1	47
859	Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology. Journal of Drug Delivery Science and Technology, 2020, 57, 101682.	1.4	22

#	Article	IF	CITATIONS
860	Natural remedies and functional foods as angiogenesis modulators., 2020,, 1-31.		3
861	Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy. Acta Pharmaceutica Sinica B, 2020, 10. 1453-1475.	5.7	16
862	Multi-targeted B and Co co-doped 45S5 bioactive glasses with angiogenic potential for bone regeneration. Materials Science and Engineering C, 2020, 112, 110909.	3.8	29
863	Post-loading of proangiogenic growth factors in PLGA microspheres. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 1-10.	2.0	12
864	The FGF/FGFR system in the physiopathology of the prostate gland. Physiological Reviews, 2021, 101, 569-610.	13.1	37
865	Bioprinting of Small-Diameter Blood Vessels. Engineering, 2021, 7, 832-844.	3.2	37
866	Deep learning with convolutional neural network in the assessment of breast cancer molecular subtypes based on US images: a multicenter retrospective study. European Radiology, 2021, 31, 3673-3682.	2.3	39
867	Self-assembled nanosheets on NiTi alloy facilitate endothelial cell function and manipulate macrophage immune response. Journal of Materials Science and Technology, 2021, 78, 110-120.	5.6	12
868	Gastric carcinogenesis: a comprehensive review of the angiogenic pathways. Clinical Journal of Gastroenterology, 2021, 14, 14-25.	0.4	18
869	Two sides of the same coin: Insights into the myoepithelial cells in carcinoma ex pleomorphic adenoma development. Critical Reviews in Oncology/Hematology, 2021, 157, 103195.	2.0	4
870	Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sciences, 2021, 264, 118642.	2.0	18
871	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
872	The delicate balance between neurotoxicity and neuroprotection in the context of HIV $\hat{a}\in I$ infection. Glia, 2021, 69, 255-280.	2.5	8
873	Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treatment and Research Communications, 2021, 28, 100422.	0.7	56
874	<i>In vitro</i> vascularization of tissue engineered constructs by non-viral delivery of pro-angiogenic genes. Biomaterials Science, 2021, 9, 2067-2081.	2.6	9
876	Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases. Journal of Cellular Physiology, 2021, 236, 6282-6296.	2.0	32
877	VEGF-Independent Activation of M $\tilde{A}^{1}/4$ ller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. International Journal of Molecular Sciences, 2021, 22, 2179.	1.8	18
878	Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Frontiers in Oncology, 2020, 10, 612802.	1.3	31

#	Article	IF	CITATIONS
879	Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. Cells, 2021, 10, 293.	1.8	27
880	Complement-mediated release of fibroblast growth factor 2 from human RPE cells. Experimental Eye Research, 2021, 204, 108471.	1.2	2
881	Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. Cancers, 2021, 13, 1422.	1.7	31
882	Multimodal treatment combining cold atmospheric plasma and acidic fibroblast growth factor for multiâ€tissue regeneration. FASEB Journal, 2021, 35, e21442.	0.2	8
883	Hypoxia during incubation and its effects on broiler's embryonic development. Poultry Science, 2021, 100, 100951.	1.5	11
885	Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health. Diseases (Basel, Switzerland), 2021, 9, 28.	1.0	6
886	Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct. Animals, 2021, 11, 1099.	1.0	2
887	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3765.	1.8	136
888	What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype. International Journal of Molecular Sciences, 2021, 22, 4415.	1.8	7
890	TGF- \hat{l}^21 polymorphism increases the risk of bleeding complications in patients on oral anticoagulant after cardiac valve replacement. Heart and Vessels, 2021, 36, 1885-1891.	0.5	1
891	Half-life modeling of basic fibroblast growth factor released from growth factor-eluting polyelectrolyte multilayers. Scientific Reports, 2021, 11, 9808.	1.6	13
892	Tavuk Embriyosu Koryoallantoik Membranında Görþlen Anjiyogenez Sürecinde C-Tipi Natriüretik Peptid-3 ve Natriüretik Peptid Reseptör-B mRNA İfadelerinin Analizi: Tanımlayıcı Bir Çalışma. Uluda Üniversitesi Tıp Fakültesi Dergisi, 0, , .	aÄX2	1
893	Neovascularization of engineered tissues for clinical translation: Where we are, where we should be?. APL Bioengineering, 2021, 5, 021503.	3.3	12
894	Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities. International Journal of Molecular Sciences, 2021, 22, 6126.	1.8	11
895	Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer. Cells, 2021, 10, 1617.	1.8	11
896	Exogenous FGF-2 prolongs endothelial connection in multilayered human skeletal muscle cell sheet. Journal of Bioscience and Bioengineering, 2021, 131, 686-695.	1.1	1
897	Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer. Cancers, 2021, 13, 2775.	1.7	10
899	The "Angiogenic Switch―and Functional Resources in Cyclic Sports Athletes. International Journal of Molecular Sciences, 2021, 22, 6496.	1.8	7

#	Article	IF	Citations
900	Gene therapy for critical limb ischemia: Per aspera ad astra. Current Gene Therapy, 2021, 21, .	0.9	2
901	Cellular Mechanisms of FGF-Stimulated Tissue Repair. Cells, 2021, 10, 1830.	1.8	25
902	Chronic intermittent hypobaric hypoxia attenuates ischemic limb injury by promoting angiogenesis in mice. Canadian Journal of Physiology and Pharmacology, 2021, 99, 1191-1198.	0.7	0
903	FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biology, 2021, 19, 173.	1.7	53
904	Three-dimensional microengineered vascularised endometrium-on-a-chip. Human Reproduction, 2021, 36, 2720-2731.	0.4	31
905	Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Therapy, 2022, 29, 908-917.	2.2	4
906	Resveratrol and endothelial function: A literature review. Pharmacological Research, 2021, 170, 105725.	3.1	83
907	Delivery of a spheroids-incorporated human dermal fibroblast sheet increases angiogenesis and M2 polarization for wound healing. Biomaterials, 2021, 275, 120954.	5.7	26
908	Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis?. Reproductive BioMedicine Online, 2021, 43, 319-328.	1.1	11
909	Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128258.	1.0	21
910	Epigenetic Regulation of Angiogenesis in Development and Tumors Progression: Potential Implications for Cancer Treatment. Frontiers in Cell and Developmental Biology, 2021, 9, 689962.	1.8	25
911	Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension. Journal of Clinical Investigation, 2021, 131, .	3.9	24
912	Magnetic Resonance Imaging Phenotypes of Breast Cancer Molecular Subtypes: A Systematic Review. Academic Radiology, 2022, 29, S89-S106.	1.3	25
913	Mechanisms underlying unidirectional laminar shear stress-mediated Nrf2 activation in endothelial cells: Amplification of low shear stress signaling by primary cilia. Redox Biology, 2021, 46, 102103.	3.9	8
915	Integrin $\hat{1}^2$ 3 targeting biomaterial preferentially promotes secretion of bFGF and viability of iPSC-derived vascular smooth muscle cells. Biomaterials Science, 2021, 9, 5319-5329.	2.6	4
916	Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Molecular Cancer, 2021, 20, 4.	7.9	102
917	Fibroblast Growth Factor-2 in Angiogenesis. , 2008, , 77-88.		2
918	Angiogenesis in the Metabolic Syndrome. , 2009, , 85-99.		3

#	Article	IF	CITATIONS
919	Proteoglycans and Osteolysis. Methods in Molecular Biology, 2012, 836, 323-337.	0.4	6
920	Gene and Cell Therapy for Critical Limb Ischemia. , 2017, , 491-501.		1
921	Mechanisms of Tumor Angiogenesis. , 2019, , 3-31.		2
922	The Role of Matrix Metalloproteinases in Cellular Invasion and Metastasis. , 2011, , 145-191.		5
923	Potential functions of embryonic cardiac macrophages in angiogenesis, lymphangiogenesis and extracellular matrix remodeling. Histochemistry and Cell Biology, 2021, 155, 117-132.	0.8	13
924	Down-regulation of TGF- \hat{l}^2 , VEGF, and bFGF in vascular endothelial cells of chicken induced by a brittle star (Ophiocoma erinaceus) extract. Heliyon, 2020, 6, e03199.	1.4	7
925	Fibroblast growth factor signalling: from development to cancer. , 0, .		1
926	Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101. Scientific Reports, 2016, 6, 30035.	1.6	7
927	The FGF system has a key role in regulating vascular integrity. Journal of Clinical Investigation, 2008, 118, 3355-3366.	3.9	257
928	Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Medical Science Monitor, 2013, 19, 1188-1194.	0.5	7
929	Fibroblast Growth Factor (FGF) Signaling Protects Against Acute Pancreatitis-Induced Damage by Modulating Inflammatory Responses. Medical Science Monitor, 2020, 26, e920684.	0.5	6
930	A Novel Fibroblast Growth Factor-1 (FGF1) Mutant that Acts as an FGF Antagonist. PLoS ONE, 2010, 5, e10273.	1.1	21
931	EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1. PLoS ONE, 2013, 8, e71449.	1.1	34
932	Genome-Wide Copy Number Variations Inferred from SNP Genotyping Arrays Using a Large White and Minzhu Intercross Population. PLoS ONE, 2013, 8, e74879.	1.1	24
933	Acidic Fibroblast Growth Factor Promotes Endothelial Progenitor Cells Function via Akt/FOXO3a Pathway. PLoS ONE, 2015, 10, e0129665.	1.1	11
934	An Integrated Analysis of MicroRNA and mRNA Expression Profiles to Identify RNA Expression Signatures in Lambskin Hair Follicles in Hu Sheep. PLoS ONE, 2016, 11, e0157463.	1.1	44
935	Endothelial angiogenesis is directed by RUNX1T1-regulated VEGFA, BMP4 and TGF- \hat{l}^2 2 expression. PLoS ONE, 2017, 12, e0179758.	1.1	28
936	Fibroblast growth factor receptor-1 mediates internalization of pathogenic spotted fever rickettsiae into host endothelium. PLoS ONE, 2017, 12, e0183181.	1.1	31

#	ARTICLE	IF	CITATIONS
937	Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression. Histology and Histopathology, 2015, 30, 13-31.	0.5	24
938	New directions in metabolic syndrome diagnosis: assessment of vascular endothelial growth factor, pentraxin-3 and transforming growth factor beta levels. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 57-61.	0.4	2
939	Systemic sclerosis and idiopathic interstitial pneumonia: histomorphometric differences in lung biopsies. Jornal Brasileiro De Pneumologia, 2009, 35, 529-540.	0.4	11
940	Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer. Oncotarget, 2017, 8, 20187-20197.	0.8	8
941	Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget, 2017, 8, 29220-29232.	0.8	10
942	Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget, 2017, 8, 82583-82592.	0.8	31
943	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-673.	0.8	57
944	A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget, 2015, 6, 13790-13802.	0.8	27
945	Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?. Oncotarget, 2017, 8, 39795-39804.	0.8	38
946	Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget, 2016, 7, 44735-44762.	0.8	141
947	Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. Current Drug Targets, 2019, 20, 852-870.	1.0	19
948	Potential Biomolecules and Current Treatment Technologies for Diabetic Foot Ulcer: An Overview. Current Diabetes Reviews, 2018, 15, 2-14.	0.6	3
949	Exosomes: novel effectors of human platelet lysate activity., 2014, 28, 137-151.		140
950	Angiogenesis: bFGF and VEGF in breast carcinoma. Archive of Oncology, 2006, 14, 126-130.	0.2	3
951	Accelerated cancer aggressiveness by viral oncomodulation: New targets and newer natural treatments for cancer control and treatment., 2019, 10, 199.		6
952	Plasma Concentrations of Fibroblast Growth Factors 21 and 19 in Patients with Cushing's Syndrome. Physiological Research, 2010, 59, 415-422.	0.4	25
953	Heparanase and hepatocellular carcinoma: Promoter or inhibitor?. World Journal of Gastroenterology, 2010, 16, 306.	1.4	19
954	Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma <i>via</i> elevation of FGFR2 expression. World Journal of Gastroenterology, 2014, 20, 18306.	1.4	25

#	Article	IF	CITATIONS
955	Heparan Sulphate-Growth Factor Interactions in Development and Disease. Trends in Glycoscience and Glycotechnology, 2005, 17, 241-253.	0.0	1
956	Article Commentary: TGF-Î ² Mediated Crosstalk between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. Cancer Growth and Metastasis, 2014, 7, CGM.S14205.	3.5	46
957	Tumor Angiogenesis: Initiation and Targeting - Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas Cancer Research and Treatment, 2006, 38, 189.	1.3	19
958	Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World Journal of Gastrointestinal Oncology, 2019, 11, 686-704.	0.8	35
959	Signaling Pathways in Liver Cancer., 0, , .		4
960	Stem cells and cardiac repair: alternative and multifactorial approaches. Journal of Regenerative Medicine & Tissue Engineering, 2013, 2, 8.	1.5	9
961	Key steps in unconventional secretion of fibroblast growth factor 2 reconstituted with purified components. ELife, 2017, 6, .	2.8	63
962	Overexpression of VEGF-C and MMP-9 predicts poor prognosis in Kazakh patients with esophageal squamous cell carcinoma. PeerJ, 2019, 7, e8182.	0.9	12
963	Angiogenic Effects and Crosstalk of Adipose-Derived Mesenchymal Stem/Stromal Cells and Their Extracellular Vesicles with Endothelial Cells. International Journal of Molecular Sciences, 2021, 22, 10890.	1.8	38
964	Application of a Mutant Cell Library to Determine the Structure–Function Relationship of Heparan in Facilitating FGF2-FGFR1 Signaling. Methods in Molecular Biology, 2022, 2303, 637-644.	0.4	0
965	Anti-Angiogenic and Cytotoxicity Effects of Selachyl Alcohol Analogues. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1913-1920.	0.9	6
966	Pro-angiogenic activity and vasculogenic mimicry in the tumor microenvironment by leptin in cancer. Cytokine and Growth Factor Reviews, 2021, 62, 23-41.	3.2	23
967	Suppression of endothelial miR-22 mediates non-small cell lung cancer cell-induced angiogenesis. Molecular Therapy - Nucleic Acids, 2021, 26, 849-864.	2.3	7
969	Correlation between steroid receptors, angiogenic factors, and classical prognostic parameters in node-negative breast cancer patients. Archives of Biological Sciences, 2009, 61, 599-605.	0.2	0
970	Cell and Tissue Interactions with Materials: The Role of Growth Factors., 2009, , 199-224.		1
971	Explant combined with trypsin-digestion for culture of endothelial cells from infantile hemangiomas. Academic Journal of Second Military Medical University, 2009, 29, 147-150.	0.0	0
972	Therapeutic effect of ¹²⁵ I in treatment of nude mice implanted with human glioma. Academic Journal of Second Military Medical University, 2010, 30, 46-50.	0.0	0
973	Cellular Cancer Processes and Their Molecular Targets for Nutritional Preemption of Cancer. , 2010, , 45-70.		0

#	Article	IF	CITATIONS
974	Interactive Signaling Pathways in the Vasculature. , 2010, , 2593-2599.		0
976	Ovarian/Primary Peritoneal Carcinoma. , 2012, , 167-203.		0
977	Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. , 2012, , 135-160.		0
978	Angiogenesis in Diabetes. Unraveling the Angiogenic Paradox. The Open Circulation & Vascular Journal, 2012, 3, 3-9.	0.4	1
979	Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms. Nigerian Journal of Clinical Practice, 2015, 18, 638.	0.2	2
981	Fibroblast Growth Factor Signaling in Vascular Development. , 2015, , 93-114.		O
982	THERAPEUTIC ANGIOGENESIS BY GROWTH FACTORS AND BONE MARROW MONONUCLEAR CELLS ADMINISTRATION: BIOLOGICAL FOUNDATION AND CLINICAL PROSPECTS. Vestnik Transplantologii I Iskusstvennykh Organov, 2015, 17, 89-111.	0.1	1
983	Fibroblast Growth Factors (Acidic: FGF-1; Basic: FGF-2) and Its Receptors (FGFR)., 2016, , 111-120.		0
984	Mechanisms of Tumor Angiogenesis. , 2016, , 1-29.		0
985	Gene Therapy for Peripheral Arterial Disease and Nursing Implications: Clinical Experience on the use of Sendai Viral Vector. International Journal of Nursing & Clinical Practices, 2016, 3, .	0.1	0
987	The Experimental Study of Tumor Growth of Recombinant Protein Fused with Cardiac Troponin I and Artificial Peptide. World Journal of Cancer Research, 2017, 07, 48-55.	0.1	0
988	Fibroblast Growth Factor in Extremities. , 2017, , 145-158.		0
989	Peri-operative Shift in Angiogenesis-Related Factors in Breast Cancer Patients. , 2017, , 55-81.		0
990	The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506.		0
991	Glioblastoma treatment: Where to now?. Integrative Cancer Science and Therapeutics, 2018, 5, .	0.1	0
994	Gallbladder Cancer: Current and Emerging Therapies. , 2019, , 197-205.		0
995	Evaluation the effect of testosterone on the number of endothelial progenitor cells and amount of SDF- $1\hat{1}_{\pm}$, PDGF, bFGF, and NO. International Journal of Preventive Medicine, 2019, 10, 214.	0.2	4
996	Histopathological Investigation of the Effect of Ozonated Water on Skin Ulcer Healing Process in Isolation Stress Mouse Model. Journal of Advances in Medical and Biomedical Research, 2019, 27, 16-24.	0.1	0

#	Article	IF	CITATIONS
998	Fibroblast Growth Factors., 2021, , 1-11.		0
999	Review of State of the Art: Growth Factor-Based Systems for Use as Bone Graft Substitutes. , 0, , 117-165.		1
1000	Plastische Chirurgie auf neuen Wegen. , 2007, , 289-306.		0
1001	Tissue Engineering – Combining Cells and Biomaterials into Functional Tissues. , 2008, , 193-214.		0
1002	Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thrombosis and Haemostasis, 2007, 97, 355-63.	1.8	37
1003	Effects of temperature and additives on stability and spectrum of a therapeutic fibroblast growth factor. DARU, Journal of Pharmaceutical Sciences, 2011, 19, 138-44.	0.9	5
1004	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-73.	0.8	33
1005	Nutrigenomics and cancer. Avicenna Journal of Medical Biotechnology, 2009, 1, 9-17.	0.2	15
1007	NCAM and FGFR1 coexpression and colocalization in renal tumors. International Journal of Clinical and Experimental Pathology, 2014, 7, 1402-14.	0.5	8
1008	Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?. Journal of Thoracic Disease, 2015, 7, 214-6.	0.6	3
1010	Antitumor Effects of Umbelliprenin in a Mouse Model of Colorectal Cancer. Iranian Journal of Pharmaceutical Research, 2018, 17, 976-985.	0.3	11
1012	FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers, 2021, 13, 5796.	1.7	32
1014	FGF Exhibits an Important Biological Role on Regulating Cell Proliferation of Breast Cancer When it Transports Into The Cell Nuclei. Cell Biochemistry and Biophysics, 2022, 80, 311-320.	0.9	2
1015	From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 1481-1504.	2.9	16
1016	Sustained Release of VEGF to Promote Angiogenesis and Osteointegration of Three-Dimensional Printed Biomimetic Titanium Alloy Implants. Frontiers in Bioengineering and Biotechnology, 2021, 9, 757767.	2.0	12
1017	Fibroblast Growth Factors. , 2021, , 665-675.		0
1018	Spatiotemporal regulation of angiogenesis/osteogenesis emulating natural bone healing cascade for vascularized bone formation. Journal of Nanobiotechnology, 2021, 19, 420.	4.2	21
1019	Modulation of anti-angiogenic activity using ultrasound-activated nutlin-loaded piezoelectric nanovectors. Materials Today Bio, 2022, 13, 100196.	2.6	8

#	Article	IF	CITATIONS
1020	New developments in the biology of fibroblast growth factors. WIREs Mechanisms of Disease, 2022, 14, e1549.	1.5	52
1021	Adult Human Vascular Smooth Muscle Cells on 3D Silk Fibroin Nonwovens Release Exosomes Enriched in Angiogenic and Growth-Promoting Factors. Polymers, 2022, 14, 697.	2.0	2
1022	Placental vascularization in middle and late gestation in the pig. Reproduction and Fertility, 2022, 3, 57-66.	0.6	0
1023	Glypican-1 drives unconventional secretion of fibroblast growth factor 2. ELife, 2022, 11, .	2.8	15
1024	A Role for Liquid-Ordered Plasma Membrane Nanodomains Coordinating the Unconventional Secretory Pathway of Fibroblast Growth Factor 2?. Frontiers in Cell and Developmental Biology, 2022, 10, 864257.	1.8	5
1025	Lymphatic Tissue Bioengineering for the Treatment of Postsurgical Lymphedema. Bioengineering, 2022, 9, 162.	1.6	6
1026	Advances in Immunomodulation and Immune Engineering Approaches to Improve Healing of Extremity Wounds. International Journal of Molecular Sciences, 2022, 23, 4074.	1.8	6
1027	Natural latex serum: characterization and biocompatibility assessment using <i>Galleria mellonella</i> as an alternative <i>in vivo</i> model. Journal of Biomaterials Science, Polymer Edition, 2022, 33, 705-726.	1.9	7
1028	Mechanistic characterization of endothelial sprouting mediated by proâ€angiogenic signaling. Microcirculation, 2022, 29, e12744.	1.0	2
1029	Giant cell angioblastoma. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 154-167.	0.1	0
1031	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. Journal of Oncology, 2022, 2022, 1-15.	0.6	18
1042	Unveiling OASIS family as a key player in hypoxia–ischemia cases induced by cocaine using generative adversarial networks. Scientific Reports, 2022, 12, 6734.	1.6	1
1043	Targeting angiogenesis in cancer therapy. Acta Medica Okayama, 2011, 65, 353-62.	0.1	22
1046	Role of fibroblast growth factor 19 in maintaining nutrient homeostasis and disease. Biomedical and Environmental Sciences, 2014, 27, 319-24.	0.2	8
1048	Cytotoxicity, Inflammatory Activity, and Angiogenesis Are Induced by Different Silicone Implants. In Vivo, 2022, 36, 1252-1258.	0.6	1
1049	Unconventional secretion mediated by direct protein self-translocation across the plasma membranes of mammalian cells. Trends in Biochemical Sciences, 2022, 47, 699-709.	3.7	14
1050	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease. Journal of Immunology, 2022, 208, 2283-2299.	0.4	2
1051	Vascular Endothelial Growth Factor (<scp>VEGF</scp>) expression in histological endometritis in the bitch: An immunohistochemical study. Reproduction in Domestic Animals, 2022, , .	0.6	2

#	Article	IF	CITATIONS
1052	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine, 2022, 77, 411-418.	1.1	6
1053	Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine, 2022, 156, 155916.	1.4	9
1055	Gestational Diabetes Mellitus and Energy-Dense Diet: What Is the Role of the Insulin/IGF Axis?. Frontiers in Endocrinology, $0,13,1$	1.5	9
1056	Nanosized carriers for delivery of angiogenic materials. , 2022, , 359-382.		0
1058	Engineered vascularized tissue organs. , 2022, , 301-316.		0
1059	Role of growth factors and cytokines in therapeutic angiogenesis. , 2022, , 85-111.		0
1060	Defining Characteristics of Angiogenesis Regulation in Advanced Human Carotid Plaques. Journal of Evolutionary Biochemistry and Physiology, 2022, 58, 825-840.	0.2	0
1061	Dynamic Interactions between Tumor Cells and Brain Microvascular Endothelial Cells in Glioblastoma. Cancers, 2022, 14, 3128.	1.7	8
1062	The impact of adipokines on vascular networks in adipose tissue. Cytokine and Growth Factor Reviews, 2023, 69, 61-72.	3.2	7
1063	Brassinin Promotes the Degradation of Tie2 and FGFR1 in Endothelial Cells and Inhibits Triple-Negative Breast Cancer Angiogenesis. Cancers, 2022, 14, 3540.	1.7	5
1064	Hormone Regulation of thrombospondin-1 mRNA in Porcine Granulosa Cells in vitro. Animal Reproduction Science, 2022, , 107048.	0.5	1
1065	VEGF-A and FGF4 Engineered C2C12 Myoblasts and Angiogenesis in the Chick Chorioallantoic Membrane. Biomedicines, 2022, 10, 1781.	1.4	1
1067	Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis. Journal of Hepatocellular Carcinoma, 0, Volume 9, 685-694.	1.8	7
1068	PAR2 promotes tumor-associated angiogenesis in lung adenocarcinoma through activating EGFR pathway. Tissue and Cell, 2022, 79, 101918.	1.0	3
1070	Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role. Biomedicine and Pharmacotherapy, 2022, 156, 113783.	2.5	8
1071	Cholesterol promotes clustering of PI(4,5)P2 driving unconventional secretion of FGF2. Journal of Cell Biology, 2022, 221, .	2.3	7
1072	PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. Journal of Inflammation Research, 0, Volume 15, 5439-5455.	1.6	1
1073	Tuning the intentional corona of cerium oxide nanoparticles to promote angiogenesis via fibroblast growth factor 2 signalling. Regenerative Biomaterials, 2022, 9, .	2.4	2

#	ARTICLE	IF	CITATIONS
1074	Molecular mechanism of VEGF and its role in pathological angiogenesis. Journal of Cellular Biochemistry, 2022, 123, 1938-1965.	1.2	30
1075	Injectable Host-Guest supramolecular hydrogel Co-Delivers hydrophobic and hydrophilic agents for enhanced wound healing. Chemical Engineering Journal, 2023, 454, 140027.	6.6	7
1076	Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process. European Journal of Medical Research, 2022, 27, .	0.9	8
1077	Emergence of nutrigenomics and dietary components as a complementary therapy in cancer prevention. Environmental Science and Pollution Research, 0, , .	2.7	3
1078	Deficiency of endothelial FGFR1 alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice. Frontiers in Pharmacology, 0, 13, .	1.6	3
1080	The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Communication and Signaling, 2022, 20, .	2.7	18
1081	Bioprinting Technologies and Bioinks for Vascular Model Establishment. International Journal of Molecular Sciences, 2023, 24, 891.	1.8	10
1082	XBP1â€elicited environment by chemotherapy potentiates repopulation of tongue cancer cells by enhancing miRâ€22/IncRNA/KAT6Bâ€dependent NFâ€PB signalling. Clinical and Translational Medicine, 2023, 13,	.1.7	2
1083	Vascular Distribution and Expression Patterns of Angiogenic Factors in Caruncle during the Early Stage of Pregnancy in Goats (Capra hircus). Animals, 2023, 13, 99.	1.0	2
1084	Insight on the cellular and molecular basis of blood vessel formation: A specific focus on tumor targets and therapy. , 2023, 2, .		1
1085	Exercise-induced skeletal muscle angiogenesis: impact of age, sex, angiocrines and cellular mediators. European Journal of Applied Physiology, 2023, 123, 1415-1432.	1.2	8
1086	Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing. Biomedicines, 2023, 11, 613.	1.4	7
1087	Synthesis of Novel Thiazolidine-4-One Derivatives, Their Cytotoxicity, Antifungal Properties, Molecular Docking and Molecular Dynamics. Russian Journal of Bioorganic Chemistry, 0, , .	0.3	1
1088	Fibronectin-Enriched Interface Using a Spheroid-Converged Cell Sheet for Effective Wound Healing. ACS Applied Materials & Interfaces, 2023, 15, 11536-11548.	4.0	1
1089	Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine. Frontiers in Pharmacology, 0, 14 , .	1.6	2
1090	Angiogenesis Inhibitors in the Treatment of Cancer. , 2023, , 1-33.		О
1091	Atf4 regulates angiogenic differences between alveolar bone and long bone macrophages by regulating M1 polarization, based on single-cell RNA sequencing, RNA-seq and ATAC-seq analysis. Journal of Translational Medicine, 2023, 21, .	1.8	1
1092	Evaluation of tumour necrosis factor alpha-stimulated gene-6 and fibroblast growth factor-2 levels in patients diagnosed with multi-system inflammatory syndrome in children. Cardiology in the Young, 0, , 1-6.	0.4	O

#	Article	IF	CITATIONS
1093	Molecular Pathology of Lung Cancer., 0,,.		0
1094	Electrical Stimulation Promotes the Vascularization and Functionalization of an Engineered Biomimetic Human Cardiac Tissue. Advanced Healthcare Materials, 2023, 12, .	3.9	7
1095	Therapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease. IScience, 2023, 26, 106577.	1.9	2
1096	Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers, 2023, 15, 2376.	1.7	1
1100	Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	68